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 ABSTRACT OF DISSERTATION 
 
 
INTERMITTENT HYPOXEMIA IN PRETERM INFANTS 
Intermittent hypoxemia (IH) is defined as episodic drops in oxygen 
saturation (SpO2). Virtually all preterm infants have IH events. Extremely preterm 
infants have hundreds of IH events per day. The extent of IH is not apparent 
clinically as accurately documenting cardiorespiratory events for day-to-day 
patient care management is challenging. High resolution pulse oximeters with 2 
second averaging time are currently the ideal methods to measure IH. We have 
developed novel methods and processes to accurately and efficiently calculate 
an IH profile that reflects to spectrum of the problem.  
The natural progression of IH is dynamic. There is low incidence of IH in 
the few 2 weeks of life, followed by a progressive increase until peak IH at 4-5 
week after which IH plateaus. Multiple factors place preterm infants at high risk 
for increased IH. These factors include respiratory immaturity, lung disease, and 
anemia. We also show that preterm infants prenatally exposed to opioids or 
inflammation (due to maternal chorioamnionitis) have increased IH measures 
compared to unexposed infants. Interestingly, the increased IH in the exposed 
groups persists beyond the immediate postnatal period.  
Brief episodes of oxygen desaturations may seem clinically insignificant; 
however, these events may have a cumulative effect on neonatal outcomes. 
There is mounting evidence from both animal models and clinical studies 
suggesting that IH is associated with injury and poor outcomes such as impaired 
growth, retinopathy of prematurity and neurodevelopmental impairment. In 
addition data from neonatal animal models and adults with obstructive sleep 
apnea suggest that IH is pro inflammatory itself. We demonstrate in this 
document for the first time in preterm infants that IH is associated with increased 
serum inflammatory marker, C-reactive protein.  
 
 
Finally, a valuable experience throughout this process is working with a 
talented and dedicated multidisciplinary team. We are a solid example of the 
value of team science during this new era of clinical and translational research. 
Our respiratory control research program is one of handful programs nationwide 
able to perform such high-fidelity studies related to cardiorespiratory events in 
preterm infants. We will continue to tackle complex questions involving health of 
infants. 
 
KEYWORDS: Intermittent Hypoxemia, Preterm Infants, Prenatal Opioid  
 Exposure, Chorioamnionitis, Inflammation  
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CHAPTER 1: INTRODUCTION AND CLINICAL RELEVANCE 
 
This chapter was published as a review article at the American Academy of 
Pediatrics NeoReviews. The following is a summary of the review with 
permission from the publisher. The full review is not open access and can be 
found at the citation below.  One section related to prenatal exposure was added 
to this chapter that was not included in the original publication.  
 
Citation: Abu Jawdeh EG. Intermittent Hypoxemia in Preterm Infants: Etiology 
and Clinical Relevance. NeoReviews. 2017 November 01; 18(11):e637-e646. 
 
I. Introduction 
 
Intermittent hypoxemia (IH), generally defined as brief, episodic drops in 
hemoglobin oxygen saturation (SpO2). Intermittent hypoxemia is a common 
disorder in preterm infants with rising evidence linking IH to neonatal morbidities 
and long term impairment.  The definition and thresholds below which IH is 
clinically relevant are debatable (1-4).  
 
II. Natural Progression 
 
Intermittent hypoxemia is inversely related to gestational age (GA) (5, 6). 
Small for gestational age (SGA) are particularly at risk to having increased IH 
compared to infants appropriate for gestational age (AGA). In addition, IH natural 
progression varies by postnatal age (1, 2). There is a low frequency of IH during 
the first week after birth, followed by a progressive increase by weeks 2-3, with a 
peak around 4-5 weeks then plateau/decrease during weeks 6-10.  The factors 
that influence the rise in IH are poorly defined (7, 8).  
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III. Factors that Influence Intermittent Hypoxemia 
 
The conventional definition of apnea of prematurity (AOP) may not be 
applicable to the causality of IH in the current extremely premature NICU 
population with lung immaturity and lung disease, because as IH can often occur 
following very brief respiratory pauses, periodic breathing or ineffective 
ventilation (9-11).  
 
The “Perfect Storm” 
The impaired  respiratory control along with  lung disease/immaturity 
create a “perfect storm”, leading to an increased  IH frequency(12). Factors that 
contribute to increased respiratory pauses and resultant IH in preterm infants 
include: upregulated inhibitory neurotransmitters, decreased central chemo-
sensitivity (7, 10, 13), paradoxical ventilatory depression in response to hypoxia 
(10, 13), hyper-excitable carotid bodies (14), immature laryngeal chemo-reflex 
(15) and low baseline functional residual capacity (FRC) (7, 10, 16). 
 
Prenatal Exposure 
 Prenatal environmental exposures such as opioids, tobacco, and other 
drugs may have a sustained effect on apnea, lung disease and subsequently IH. 
Prenatal opioid exposure alters the response to carbon dioxide and depresses 
central respiratory control centers (17-21). Opioids are known to suppress 
breathing and respiratory effort especially in neonates (22). Opioid exposed 
infants often show intrauterine growth retardation and meconium staining, two 
hallmarks of fetal hypoxia. Similar to the literature from sudden infant death, 
prenatal opioid use may increase cardiorespiratory events in preterm infants. 
Prenatal opioids, especially street heroin, cause chronic intrauterine hypoxia 
leading to brainstem gliosis damaging the central respiratory centers; hence 
likely more apnea events (19). In addition, infants with intrauterine exposure to 
drugs of abuse have “down-regulation” of placental neurotransmitter receptors 
(23). Abnormalities or depletion of receptor sites, especially if the same process 
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occurs in the fetal brain, could impair function of the normal neonatal respiratory 
control network leading to frequent or prolonged apnea and subsequent IH. 
Furthermore, prenatal exposure to other illicit drugs such as cocaine perturbs, 
albeit subtly, the maturation of respiratory control, resulting in disruption of 
postnatal respiration (24). Prenatal tobacco use is common; around 22% of 
mothers smoke while pregnant in the USA (25). Prenatal nicotine exposure 
increased apnea in neonatal mice (26). In addition, studies evaluating pulmonary 
mechanics in infants of smoking mothers indicated prenatal exposure affects 
pulmonary function by altering expiratory flow profiles, reducing respiratory 
compliance and increasing airway resistance (25, 27). Furthermore, prenatal 
tobacco alters chemoreceptor sensitivity and blunts response to hypoxia in 
infants (25, 28). Given the rising epidemic of drug abuse in the USA, a larger 
cohort aimed at understanding these relationships, especially opioids, is 
imperative and may have a direct impact on management of preterm infants.  
 
Role of Inflammation  
Inflammation increases apnea events and worsens lung disease; 
subsequently increasing IH (29-31). However, because IH is pro-inflammatory, 
the relationship between inflammation and IH may be bidirectional (7, 14, 32-35). 
 
Anemia 
Preterm infants with anemia are at increased risk for IH. As the hematocrit 
level decreases, the probability of apnea, bradycardia and IH events increases 
(1, 16, 36).  
 
Target Oxygen Saturation 
The target oxygen saturation influences the frequency of IH (8, 37). A 
lower SpO2 target is associated with greater incidence of IH events compared 
with higher SpO2 target (16).  
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IV. Monitoring  
 
Intermittent hypoxemia is very common in preterm infants with hundreds 
of events per day and accurately documenting those events by bedside providers 
is challenging without continuous automated recordings (1, 38, 39).  
 
V. Consequences 
 
There is rising evidence linking IH to neonatal morbidities and long term 
impairment. These brief episodes of oxygen desaturations have been implicated 
in the following. Data from animal models:  neurocognitive handicap, impaired 
myelination, decreased neuronal integrity, long-term neuro-functional deficits, 
increased inflammation and oxidative stress, impaired growth and sleep 
disordered breathing/apnea (32, 40-42). Data from human studies: Retinopathy 
of prematurity (ROP), Neurodevelopmental Impairment (NDI) (cognitive, motor 
and language delay) and death (3, 5, 43-46).  
 
VI. Conclusion 
 
Although IH is very common in preterm infants the extent of the problem is 
often underestimated by clinical providers. Multiple factors in preterm infants 
increase their risk for significant IH.  Intermittent hypoxemia is clinically relevant 
with rising evidence from both animal models and preterm infants linking IH to 
poor outcomes.  
 
 
 
 
 
 
 
5 
 
CHAPTER 2: METHOD DEVELOPMENT AND VALIDATION 
 
 
I. Introduction 
 
Intermittent hypoxemia is a common problem in preterm infants due to 
their immature respiratory control (apnea of prematurity) and lung 
immaturity/disease (BPD). All preterm infants are at risk for IH. Extreme preterm 
infants have highest risk for IH, due to their extremely immature respiratory 
control and lung immaturity/disease. When oxygen saturation (SpO2) is 
continuously recorded, extreme preterm infants have on average 150 to 200 
severe IH events per day during which their SpO2 drops below 80% (1). 
Intermittent hypoxemia (IH) is defined as episodic drops in blood oxygen 
saturation. The specific definition of oxygen saturation (SpO2) drop varies by 
research group, however most consider SpO2 drop to less than 80% as 
significant (1-3, 36). Others consider a SpO2 of less than 90% as the starting 
point (4). Calculating and establishing an IH profile that reflects the spectrum of 
IH in terms of frequency, severity and duration is imperative.  
Accurately documenting cardiorespiratory events for day-to-day patient 
care management is challenging, as the extent of IH is not apparent clinically. 
Pulse oximeters are the current standard of care for monitoring oxygenation in 
the Neonatal Intensive Care Unit (NICU). Bedside providers under-recognize the 
number of events compared to objective automated recordings. In one study, 
compared to polysomnography, nursing staff recorded less than 30% and 40% of 
IH and bradycardia events, respectively. The shorter the event, the less likely 
that it was recognized by nursing staff (36). For example, bedside providers 
documented 35% and 29% of IH events that lasted greater than 20 and 10 
seconds, respectively (38). Pulse oximeters are the current standard of care for 
monitoring oxygenation in the NICU. Hence, continuous physiologic recording is 
required for accurate detection of IH.  
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In this section we describe the development of methods for SpO2 
recording, filtering, analyses, selection of outcome measures and validation of 
our novel programs.  
 
II. Data Acquisition 
 
Oxygen saturation data were prospectively collected from preterm infants 
admitted to our level 4 NICU starting November 2014. We used Masimo Radical 
7 (Masimo, Irvine, CA) pulse oximeters for continuous data acquisition. Masimo 
pulse oximeters are widely used in NICUs worldwide due to their proprietary 
Signal Extraction Technology (SET®) that measures through motion and low 
perfusion; both important considerations in preterm infants (37, 47-52). All our 
research pulse oximeters were updated to the latest software prior to study 
initiation.  
Pulse oximeters were equipped with serial data recorders (Acumen 
Instruments Corp) for continuous data collection (4). The Acumen recorders were 
connected to the RS232 port located on the Masimo pulse oximeter docking 
station. Data was collected with 1Hz frequency (every second) and saved on 
compact flash memory cards connected to the serial data recorders. The 
compact flash memory cards saved data continuously and were manually 
downloaded by research personnel to our encrypted servers provided by the 
University of Kentucky. We programed the Acumen recorders to save the data in 
daily files (midnight to midnight). The daily files were easier to transfer due to 
smaller size. In addition, the daily files provided a visual check of data loss if any 
and troubleshooting if necessary. The Acumen serial data recorder provided a 
time stamp (date and time, including seconds) for every second of data 
download. Time stamping is important while linking our IH data to other outcome 
measures. We downloaded data from serial data recorders weekly. Initially we 
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had difficulty with memory cards not being reliable leading to data loss. However, 
that problem was transient and resolved with a different brand of memory cards.  
We also trialed a different serial data recorder (SeriaGhost Logger) that 
was placed in series with the Acumen recorders. The SerialGhost recorders were 
reliable and stored data accurately. The SerialGhost saved all data in one file 
that at times was tens of gigabytes in size before post processing. The 
SerialGhost utilized the timestamp from the pulse oximeters versus the Acumen 
which had its own time stamp (in addition to that of the pulse oximeters). The 
SerialGhost had the capacity for timestamping however in our experience it was 
not reliable and was not linked to every second of data download. The 
SerialGhost was downloaded once at the end of the study period as downloading 
weekly was not feasible in the absence of a memory card. We tested a 
SerialGhost with Wi-Fi capabilities. The goal was to download directly to our 
encrypted serves. This was more challenging than expected given both 1) 
hospital network restrictions and 2) network changes upon moving infants from 
one room to another. Currently, we only use the Acumen serial data recorders.   
A research monitoring unit is connected to the patient after informed 
consent is obtained. Initially we docked our research units to the clinical stations 
and utilized the same pulse oximeter for both for clinical and research purposes. 
An alarm delay was set to avoid alarm fatigue. However, the serial data 
recorders were sometimes left behind when moving patients among rooms. Early 
during our study period we changed this practice and currently we utilize an 
additional research pulse oximeter that moves with the patient. The research 
pulse oximeter alarm settings are silenced to avoid further noise and alarm 
fatigue. Patients are connected to the additional research pulse oximeter upon 
enrollment and monitored for first 2 months of life or 36 weeks corrected age, 
whichever came last.  
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Averaging Time 
Pulse oximeters are the current standard of care for monitoring 
oxygenation in the NICU. However, the monitor settings, such as the averaging 
time, affects the number of IH events recorded (39). Pulse oximeters average 
SpO2 values over several heartbeats. Pulse oximeters set to longer averaging 
times underestimate IH events of short duration and overestimate events of 
longer duration. This is likely as a result of several short events merged together 
as one prolonged event (Figure 2.1). Clinical pulse oximeters are set to longer 
averaging time to decrease alarm fatigue for bedside providers (53). The default 
averaging times in clinical pulse oximeters range between 8 to 10 seconds but 
can be as long as 16 seconds. An option for centers who wish to use shorter 
averaging time is setting a longer alarm delay time (10 to 15 seconds) to reduce 
alarm fatigue (53). For research purposes, similar to other groups who study IH, 
we utilized high-resolution pulse oximeters with 2-second averaging time for 
continuous SpO2 monitoring (1, 2). We confirmed and tracked the pulse oximeter 
settings weekly during data download.  
  
III. Data Filtering and Processing 
 
In collaboration with biomedical engineering (Dr. Abhijit Patwardhan 
laboratory) we developed novel programs to filter and process SpO2 data to 
analyze IH. Both algorithms were developed using Matlab (Matlab, Natick, MA).  
The IH data filtering program excluded artifacts based on both the EXC 
code provided by Masimo monitors and missing variables in the output. The 
filtering program imported the raw data in text (.txt) format and exported clean 
data in text (.txt) format as well. The exported data files were automatically 
organized daily by the algorithm. The daily file names included the patient 
identification number and the date of the recorded data. The filtering algorithm 
has the capacity to filter multiple patients at the same time.  
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The second program is called Intermittent Hypoxemia Automated 
Analyses Algorithm (IH-AAA). The IH-AAA process the filtered data files to 
analyze the IH profile (below).  The algorithm imported the clean daily text files (1 
Hz frequency) and exported analyzed IH outcome measures in excel files 
averaged over different durations and intervals (weekly, daily, hourly). This 
program has the capacity to analyze multiple patients at the same time. The 
algorithm exports multiple excel files for every patient to reflect the spectrum of 
IH of different durations (e.g. 4-180 seconds, >180 seconds, etc.) and intervals 
(weekly, daily, hourly). Each excel file is labeled with patients identification 
number, date of the recorded data and interval. The IH-AAA also has the 
capacity to filter raw data in text files.  
 
IV. Intermittent Hypoxemia Profile 
 
The clinical relevance of IH is a relatively new observation (2) with no 
accurately defined threshold below which IH leads to morbidities and impairment;  
the exact definition of IH is controversial (54). Therefore, we developed a 
program that accounts for IH at multiple thresholds and calculate an IH profile.  
The IH profile reflects the continuum of the IH problem making it possible to 
demonstrate at what level IH causes injury.  
In this section we describe the IH profile. For the purpose of 
demonstration we used a sample patient. We selected the second patient 
enrolled in our cohort (IH0002). The first patient had an early death and does not 
have a complete data set.   
Frequency 
The number of IH events is calculated for every interval (weekly, daily, 
hourly). The frequency of IH is a primary outcome measure that has been utilized 
by us and other groups and linked to neonatal morbidities and mortality (1, 2, 4, 
55, 56). We define severe IH events as a SpO2 drop to less than 80% (IH-
 
10 
 
SpO2<80). Moderate and mild IH are defined as a drop in SpO2 to less than 85% 
(IH-SpO2<85) and 90% (IH-SpO2<90), respectively. An additional outcome 
measure is calculated based on Rhein et al. where mild IH is calculated based on 
a change from baseline by more than 4% and to SpO2<90 (IH-SpO2<90 (>4% 
Drop))(4). We have the capacity to change our thresholds for IH frequency. Our 
program outputs frequency of IH at different intervals (weeks, days, hours) as 
represented in Figure 2.2. An upper threshold is often set for IH to differentiate 
intermittent from sustained hypoxemia. We also document sustained hypoxemia 
measures.   
Similar to IH, hyperoxemic events are calculated. Documenting 
hyperoxemia is important given both the associated morbidities and to assess 
fluctuations in oxygenation. We currently have the hyperoxemia severity set at 2 
thresholds with SpO2 more than 95% (IH-SpO2>95) and 97% (IH-SpO2>97). 
Sample patient for hyperoxemic events frequency is presented in Figure 2.3.  
Percent time   
The percent time in hypoxemia is another primary measure. The benefit of 
this outcome measure is that it represents cumulative IH events of short and long 
duration. The same 3 SpO2 thresholds for percent time in hypoxemia are 
selected here for severe (%time-SpO2<80), moderate (%time-SpO2<85) and 
mild hypoxemia (%time-SpO2<90 and %time-SpO2<90 (>4% drop)) (Figure 
2.4). This measure of percent time spent with SpO2 below threshold was chosen 
per Poets et al. (3). Percent time is calculated at multiple intervals (weeks, days, 
hours). Similarly, hyperoxemia is analyzed demonstrating percent time spent with 
SpO2 more than 95% and 97%, (Figure 2.5). Percent time outcome measure is 
not affected by averaging time and is clinically relevant in all NICUs (39).  
Mean, Nadir and Peak 
The mean, nadir and peak SpO2 measures provide an additional 
perspective for IH. Mean is calculated for every interval (weeks, days, hours) and 
provides a baseline for IH during that interval (Figure 2.6). Both an average nadir 
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for all events and lowest nadir are calculated. The nadir provides insight 
regarding the severity of IH (Figure 2.7). Similarly the average peak and highest 
signal are calculated for every interval (weeks, days, hours), (Figure 2.8).   
Duration 
The duration of IH is addressed in multiple forms. First, the average 
duration of IH events below every threshold is calculated for the three intervals 
(weeks, days, hours) (Figure 2.9). Similarly the average duration is calculated for 
hyperoxemia (Figure 2.10). However, the duration of IH may vary widely and the 
average duration may not be representative as it is influenced by outliers. Hence, 
we developed our algorithm to output multiple files of different duration cutoffs 
(for example multiples of 60 seconds). E.g. 1-59seconds, 60-119 seconds, 120-
179 seconds, 180-239 seconds, 240-299, >300 seconds. By dividing the duration 
cutoffs, the average duration is influenced less by outliers. The duration cutoffs 
can be easily adjusted to any duration (for example multiples of 30 seconds, etc.) 
In addition, we use the 4-180 second cutoff for the primary measure as 
previously described by Abu Jawdeh et al. and Rhein et al. (1, 4). 
Bradycardia 
 Heart rate decelerations or bradycardia events are part of the apnea of 
prematurity problem. Our algorithm calculates bradycardia below 2 thresholds of 
80 and 100 beats per minute (bpm) (Figure 2.11) (11). The relative time of 
bradycardia to IH is also calculated. However, the role of heart rate deceleration 
is beyond the scope of this document.  
Perfusion Index 
Perfusion index (PI) is a noninvasive measure of perfusion thought to 
reflect the general hemodynamic status of the preterm infant (57, 58).  Perfusion 
index assesses the pulse strength derived from pulse oximetry. Perfusion index 
is measured by infrared light, and is calculated as the ratio of the pulsatile to non-
pulsatile components of the blood flow in tissue. The value of PI has been 
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demonstrated in multiple neonatal morbidities (59, 60), including prediction of 
patent ductus arteriosus patency shown from this cohort (61). Figure 2.12 
demonstrates PI in a sample patient.  
 
V. Statistical Analyses 
 
Statistical modeling must account for the covariance among repeated 
measurements from the same subject. A general strategy to do so is to use linear 
mixed models, also known as linear multilevel models, hierarchical models, or 
multivariate Gaussian models (62). Correctly accounting for this correlation will 
ensure standard errors are appropriately estimated, thus yielding correct p-
values and thus valid inference. Furthermore, in our experience and elsewhere, 
the need for an appropriate transformation, such as the square root, is needed 
for IH-based measures (2).  
In order to attain valid inference, the model for the mean structure of the 
given outcome over time, as well as the model for the covariance among 
outcomes from the same subject (not of interest to the research question, but a 
necessity for inference), must be correctly specified (62). Otherwise, inference 
may be biased. A simple solution to this issue is to look at outcomes aggregated 
over weekly periods; e.g., weekly IH totals.  In such a case, a statistical model 
can treat time as categorical to ensure a correctly specified mean structure with 
respect to time. Furthermore, a working unstructured covariance can be used 
with such a mean structure to ensure appropriate standard error estimation.  
Finally, this flexible modeling of the mean and covariance structures allows 
inference to be valid if any missing data are missing completely at random 
(MCAR) or missing at random (MAR) (63).  
Outcome data is sometimes not captured for periods of time for example 
due to patient leaving the NICU for procedures or imaging. Therefore, as 
outcomes are usually aggregated over time, e.g. the total IH count for a given 
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weekly period, such outcomes should be weighted by the amount of time they 
were observed. For instance, if interest is in weekly IH count, but IH data were 
only obtained for exactly half of the week, then that subject’s total IH count would 
need to be doubled for use in the statistical analysis such that it represents the 
desired weekly total. A weight of one half would then need to be assigned to this 
outcome value in the analysis. If this weighting procedure is not done, estimated 
means and standard errors may be biased.    
 
VI. Validation 
 
In order to validate the novel program, we performed an assessment 
comparing IH measures calculated by the algorithm to those of independent 
observers. The observers were masked (blind) to the algorithm analyses. We 
obtained SpO2 data from 20 preterm infants less than 30 weeks GA randomly 
selected from our cohort. A total of 60 hours were analyzed. Each subject 
contributed 3 hours of SpO2 data; 1 hour from each postnatal age epoch (1 
week, 1 months and end of study period) as defined by Abu Jawdeh et al. (1). 
We included IH events 4-180 second duration per Abu Jawdeh et al. (1). The 
validation presented focuses on two primary measures, IH-SpO2<80 and %time-
SpO2<80. Other thresholds of less than 85% and 90% were examined with 
similar results. 
The observers were masked to both other observers and algorithm 
counts. Three observers manually counted the first measure of IH-SpO2<80 from 
the raw data. The second measure of %time-SpO2<80 was analyzed by a 
singled masked observer utilizing Microsoft Excel (Excel Version 2010). Pearson 
correlations among observers and algorithm were performed using GraphPad 
(Prism 7). There was excellent correlation among observers as presented in 
Figure 2.13. For IH-SpO2<80, there was excellent correlation between mean 
observer count and algorithm count as presented in Figure 2.14. For %time-
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SpO2<80, there was excellent correlation between observer and algorithm as 
presented in Figure 2.15. 
 
VII. Discussion  
 
There is rising evidence linking IH to both short and long term morbidities 
in preterm infants and hence, accurate recording of these events is paramount in 
determining their impact. In this chapter we described methods development to 
collect and process SpO2 data to measure IH. We defined our IH outcome 
measures with emphasis on IH profile. Finally, we presented the process for 
validating IH-AAA for accurate and reliable measurement of IH. We have 
developed an automated, convenient, and time efficient strategy to record such 
events, with exceptional accuracy when compared to human measurements.  
The clinical significance of IH in preterm infants is a relatively new 
observation (2, 3, 54). In the past, brief IH events occur hundreds of times per 
day seemed clinically insignificant.  However in the last 5-10 years, the interest in 
accurately documenting these IH events increased given the recent evidence 
linking IH to neonatal morbidities. Accurately documenting IH should involve a 
continuous physiologic recording with an automated system as bedside providers 
under-recognize the number of events (36, 38). An important factor in continuous 
monitoring is averaging time of pulse oximeters. As longer averaging times will 
underestimate IH events of short duration and overestimate events of longer 
duration (39, 64). This is likely as a result of several short events merged 
together as one prolonged event (39, 64). 
An additional challenge relates to IH is variation in definitions. This 
variation is likely related to the unknown thresholds below which IH leads to 
injury. Most centers however consider a SpO2 drop to less than 80% as clinically 
relevant. We developed an IH profile that represents the continuum of IH. The IH 
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profile allows us to better define at what threshold (e.g. severity, duration, etc.) IH 
matters clinically.  
 In conclusion, over the last 5 years we developed efficient and validated 
methods to accurately assess IH. We are one of few centers in the nation able to 
perform high fidelity studies related to IH in preterm infants.  
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Figure 2. 1: A sample showing the effect of averaging time on the number 
of IH events. 
A) The 2 second averaging time recording shows 3 events IH-SpO2<90, 3 event 
IH-SpO2<85 and 2 event IH-SpO2<80. In contrast, 16 second averaging 
conversion shows 1 event IH-SpO2<90, 3 events IH-SpO2<85 and 1 event IH-
SpO2<80. B) This figure zooms in to seconds 40-60 to show how increased 
averaging time smooths the waveform by merging multiple short events. 
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Figure 2. 2: Sample demonstration of frequency of IH events averaged over 
3 intervals (weeks, days and hours). 
The graphs present IH below multiple thresholds: IH-SpO2<90 (>4% Drop), IH-
SpO2<90, IH-SpO2<85 and IH-SpO2<80.  
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Figure 2. 3: Sample demonstration of frequency of hyperoxemic events 
averaged over 3 intervals (weeks, days and hours). 
The graphs present hyperoxemia events with SpO2 greater than 95% (IH-
SpO2>95) and 97% (IH-SpO2>97). 
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Figure 2. 4: Sample demonstration of percent time spent with SpO2 below 
thresholds averaged over 3 intervals (weeks, days and hours). 
The graphs present percent time below multiple thresholds: %time-SpO2<90 
(>4% Drop), %time-SpO2<90, %time-SpO2<85 and%time-SpO2<80.  
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Figure 2. 5: Sample demonstration of percent time spent with SpO2 above 
thresholds (hyperoxemia) averaged over 3 intervals (weeks, days and 
hours). 
The graphs present percent time with SpO2 greater than 95% (%time-SpO2>95) 
and 97% (%time-SpO2>97). 
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Figure 2. 6: Mean SpO2 presented at different intervals (weeks, days, 
hours) from a sample patient.  
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Figure 2. 7: Mean average nadir and lowest SpO2 signal presented at 
different intervals (weeks, days, hours) from a sample patient.  
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Figure 2. 8: Mean average peak and highest SpO2 signal presented at 
different intervals (weeks, days, hours) from a sample patient. 
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Figure 2. 9: Mean average duration of IH events presented at different 
intervals (weeks, days, hours) from a sample patient.  
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Figure 2. 10: Mean average duration of hyperoxemia events presented at 
different intervals (weeks, days, hours) from a sample patient. 
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Figure 2. 11: Sample demonstration of bradycardia events averaged over 3 
intervals (weeks, days and hours). 
The graphs present heart rate deceleration below two thresholds of 100 beats 
per minute (bpm) and 80bpm.   
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Figure 2. 12: Mean perfusion index (PI) presented at different intervals 
(weeks, days, hours) from a sample patient. 
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Figure 2. 13: Inter-observer Pearson correlations among observers for the 
number of IH events (IH-SpO2<80). 
(A) Observer 2 vs. Observer 1. (B) Observer 3 vs. Observer 1 (C) Observer 3 vs. 
Observer 2. 
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Figure 2. 14: A Pearson correlation comparing mean observer counts 
versus those calculated by IH Automated Analyses Algorithm (IH-AAA) for 
IH-SpO2<80 
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Figure 2. 15: A Pearson correlation comparing observer calculation versus 
IH Automated Analyses Algorithm (IH-AAA) for %time-SpO2<80 
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CHAPTER 3: PRENATAL OPIOID EXPOSURE AND INTERMITTENT 
HYPOXEMIA 
 
Citation: This chapter was published as an original manuscript in Frontiers in 
Pediatrics: This chapter was not altered from the original publication.  
Abu Jawdeh EG, Westgate PM, Pant A, Stacy AL, Mamilla D, Gabrani A, 
Patwardhan A, Bada HS, Giannone P. Prenatal Opioid Exposure and Intermittent 
Hypoxemia in Preterm Infants: A Retrospective Assessment. Front Pediatr. 2017 
Dec 6;5:253. doi: 10.3389/fped.2017.00253. 
 
 
I. Introduction 
 
 Intermittent hypoxemia (IH) is defined as brief, episodic drops in oxygen 
saturation (SpO2) (1, 2). Preterm infants are at increased risk for IH due to their 
respiratory control instability/apnea of prematurity superimposed on immature 
lung structure/function. Intermittent hypoxemia in preterm infants can persist 
beyond discharge from the neonatal intensive care unit (NICU) (4). Brief 
episodes of oxygen desaturations may seem clinically insignificant, but these IH 
episodes, occurring up to hundreds of times per day, have a cumulative effect on 
neonatal morbidity and mortality. There is ample evidence showing a significant 
effect of IH on neurocognitive handicap, decreased neuronal integrity, increased 
inflammation and oxidative stress, and impaired growth (32, 41). Furthermore, IH 
has been linked to severe retinopathy of prematurity and long term 
neurodevelopmental impairment such as worse language and motor outcomes 
(2, 3, 43, 44) (45). The clinical relevance of IH is a relatively new observation with 
the advent of high-resolution pulse oximeters and assessing factors that 
influence IH is imperative.  
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There is a rise in substance misuse in the USA reaching a nationwide 
epidemic (65-70). There is an urgent need to understand the impact of prenatal 
opioid exposure on neonatal outcomes (41). Opioid exposure is associated with 
long-term neurobehavioral and developmental impairment in infants (71-78). 
Opioids are known to suppress breathing and respiratory effort especially in 
neonates (22). Since most mothers who misuse opioids have also been found to 
smoke and use poly-drugs that affect breathing pattern, it has been challenging 
to assess the isolated effect of prenatal opioid exposure on respiratory outcomes. 
Prenatal tobacco exposure alters respiratory control and worsens lung function 
(25-28, 79). Prenatal exposure to other illicit drugs such as cocaine perturbs 
maturation of respiratory control, resulting in disruption of postnatal respiration 
(24). Only few studies were able to assess the effect of isolated opioid exposure 
on neonatal respiratory outcomes. However, these studies included mostly later 
preterm and term infants or were limited to short monitoring times and small 
sample sizes (17, 80). In this study, we utilize continuous high resolution pulse 
oximeters to assess the relationship between isolated prenatal opioid exposure 
and IH in preterm infants during the first 2 months of life.  
 
II. Methods 
 
Study Design and Data Collection 
Oxygen saturation data were prospectively collected from 130 preterm 
infants less than 30 weeks gestational age (GA) admitted to our level 4 NICU 
between November 2014 and April 2017. We used high resolution pulse 
oximeters (Radical 7: Masimo, Irvine, CA) set at 2 second averaging time and 
1Hz sampling rate to continuously monitor patients during the first 8 weeks of life. 
In order to differentiate intermittent from sustained hypoxemia, we included 
events between 4-180 seconds (1). The exact threshold below which IH is 
clinically significant is controversial. A drop in SpO2 to less than 80% is widely 
 
33 
 
considered to be clinically relevant (1-3). Therefore, the primary outcome 
measure was defined as percent time spent with SpO2 below 80% (%time-
SpO2<80). The secondary outcome measure was defined as the number of 
severe IH events with SpO2 less than 80% (IH-SpO2<80).  Other outcome 
measures such as length of stay and neonatal morbidities were collected.   
Pulse oximeters were equipped with serial data recorders (Acumen 
Instruments Corp) for continuous data collection. Novel programs were utilized to 
filter and analyze data (Matlab, Natick, MA) (1, 61). Data with artifacts were 
excluded. Only SpO2 data with good signal were included in the analyses. 
Preterm infants less than 30 weeks GA were included. Infants with major 
congenital malformations were excluded.  
Data related to substance misuse and tobacco use were retrospectively 
collected from medical charts. If a mother chronically used prenatal opioids and/or 
the maternal/neonatal drug screens were positive for opioids, then the infant was 
considered for screening. Infants were then excluded from the study if the mother 
used tobacco, alcohol, or other drugs (such as cannabis); i.e., in order to assess for 
isolated opioid exposure, patients with any other exposure were excluded.  Infants 
in our cohort who were not exposed to opioids, tobacco, or other drugs served as 
controls. Neonatal meconium or urine drug screens are performed in the immediate 
newborn period. Positive drug screens due to opioids and other medications used 
for pain or sedation during delivery were excluded, as they do not represent 
prenatal misuse. Tobacco and alcohol use were collected from mothers’ medical 
records, as the toxicology screens at our hospital do not test for alcohol or tobacco 
exposure. The study was approved by the University of Kentucky Institutional 
Review Board, and informed consent was obtained prior to SpO2 data acquisition. 
Statistical Analysis 
Descriptive statistics for continuous variables are presented as either the 
mean with standard deviation or median with interquartile range, and frequencies 
and percentages are given for categorical variables.  Two-sample t-tests and 
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Wilcoxon two-sample tests were used to compare opioid exposure to non-
exposure with respect to continuous variables, and chi-square or Fisher’s exact 
tests were used for categorical variables.  To compare opioid exposure to non-
exposure with respect to IH measures over time, we utilized multivariate 
Gaussian linear modeling in order to account for repeated measurements from 
subjects, and to adjust for the potential confounders of gestational age, birth 
weight, APGAR score at 5 minutes of life, gender, and the use of prenatal 
steroids.  In order to meet statistical assumptions in these models, the square 
root of the IH measures was taken. Furthermore, weekly observations were 
weighted by the percentage of time IH was tracked during the given week.  
Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, N.C.), and all 
tests were two-sided with a 5% significance level. 
 
III. Results 
 
Of the 127 infants in our database with complete data sets, 19.7%, 29.1%, 
and 4.7% were prenatally exposed to opioids, tobacco and cannabis, 
respectively. None were exposed to alcohol, cocaine and other illicit drugs. 
Opioid exposed infants were positive for buprenorphine metabolites (64%), 
oxycodone (16%) and other opioids such as heroin and fentanyl (20%). A total of 
82 infants qualified for analysis as they were either unexposed to any illicit 
drug/tobacco (n=68) or exposed to opioids only (n=14). Figure 3.1 presents the 
flow diagram for patient eligibility and exclusion.   
There were no significant differences in baseline characteristics as 
presented in Table 1. The mean GA was 27 weeks in both groups. There were 
no significant differences in birth weight, gender and Apgar scores at 5 minutes 
of life. The vast majority of infants received prenatal steroids with no difference 
between groups. There were no significant differences in respiratory outcomes 
and neonatal morbidities between groups as presented in Table 2. Our cohort 
included preterm infants less than 30 weeks GA. Essentially all infants had 
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respiratory distress syndrome and received surfactant. Severe 
bronchopulmonary dysplasia, postnatal steroids use for lung disease, and 
oxygen need at 28 days, 36 weeks postmenstrual age and at discharge did not 
differ between opioid exposed and unexposed groups (all p=NS). Other neonatal 
morbidities such as patent ductus arteriosus, late onset sepsis, and necrotizing 
enterocolitis did not differ between groups (all p=NS). None of the exposed 
infants died versus 9 deaths in the unexposed group (p= 0.35). The median 
length of stay was 17 days longer in the opioid group (85 days) compared to 
unexposed group (68 days); however, the results were not statistically significant 
(p=0.32).  
There was a statistically significant increase in our primary outcome 
measure, %time-SpO2<80, as represented in Figure 3.2. The estimated 
difference in the means of the square root of %time-SpO2<80 was 0.23 [95% CI: 
(0.03, 0.43), p=0.03]. The mean number of IH events was estimated to be 2.95 
[95% CI: (-0.35, 6.25), p-value = 0.08] higher in the opioid exposed group, as 
represented in Figure 3.3; however, this did not reach statistical significance. 
Note that these results represent the square root of means in order to meet 
statistical assumptions in these models; estimated medians for IH measures are 
calculated using our model results and are presented in Figures 3.2B and 3.3B. 
Given increased death in the unexposed group, we then analyzed data excluding 
deaths, and results were similar. Specifically, there was a statistically significant 
increase in our primary outcome measure (%time-SpO2<80) in the opioid 
exposed compared to the unexposed group, with an estimated mean difference 
(square root) of 0.24 [95% CI: (0.05, 0.44), p-value = 0.02]. Furthermore, the 
mean number of IH events was estimated to be 2.98 [95% CI: (-0.20, 6.16), p-
value = 0.07] higher in the opioid exposed group, not quite reaching statistical 
significance.  
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IV. Discussion 
 
These results suggest that prenatal opioid exposure is associated with 
increased IH measures compared to unexposed preterm infants. This study has 
two main findings. First, interestingly, the increased IH measures in opioid 
exposed infants persisted beyond the early postnatal period. Preterm infants 
were continuously monitored with high resolution pulse oximeters during the first 
2 months of life. Second, we had the unique opportunity to assess the 
relationship between isolated opioid exposure and respiratory instability in 
preterm infants. It was challenging in the past to assess the relationship between 
isolated prenatal opioid exposure and respiratory outcomes/IH, as the majority of 
women who use opioids also smoke or misuse poly-drugs. Given our cohort 
demographics, we had the ability to report this association in infants exposed to 
opioids only.  
Another interesting secondary finding in our study is the steady increase in 
IH in the first month of life before plateauing and then decreasing. This natural 
progression of IH has been described before from another cohort of preterm 
infants less than 28 weeks GA (1, 2). Our study replicates this finding from a new 
cohort of preterm infants less than 30 weeks GA. The rise in IH may be related to 
peripheral chemoreceptor dysregulation and development of lung disease (7). 
Patients in our opioid exposed and unexposed groups did not significantly 
vary in terms of baseline characteristics (such as age, weight, gender) and 
neonatal morbidities (such as lung disease, patent ductus arteriosus, late onset 
sepsis and necrotizing enterocolitis). In addition, we adjusted in the model for 
factors that may influence oxygenation in preterm infants such as GA and 
prenatal steroids. The finding of 9 deaths in the unexposed group compared to 
no deaths in the opioid exposed group may be due to chance. Secondary 
analyses excluding deaths showed similar results with increased IH in the opioid 
exposed group. A significant secondary finding in this study is the high 
prevalence of tobacco and drug exposure in our cohort of preterm infants. The 
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frequency of opioid exposure in our preterm population is higher than previously 
reported, thus creating urgency toward addressing this significant problem in this 
vulnerable patient population (65, 67-70). 
There are multiple proposed mechanisms by which prenatal opioid 
exposure may affect breathing patterns and subsequent persistent IH in preterm 
infants. Prenatal opioid exposure alters the response to carbon dioxide and 
depresses central respiratory control centers (17-21); a main driver for 
respiratory output. Olsen et al demonstrated a blunted response to carbon 
dioxide in methadone exposed infants compared to controls (17). Ali et al 
compared the response to hypercarbia among three groups of term patients who 
were exposed to tobacco/substance misuse, tobacco alone, and unexposed 
controls. The authors showed a lower increase in central respiratory drive in 
response to hypercarbia in infants exposed to substance misuse as compared to 
tobacco alone and unexposed controls (18). Another mechanism that explains 
our results may be related to in utero hypoxia related to opioids. Prenatal opioids, 
especially street heroin, cause chronic intrauterine hypoxia leading to brainstem 
gliosis, resulting in injury to the central respiratory network. This may lead to 
respiratory instability and subsequent IH (19). Finally, data from animal models 
showed that exposure to opioid agonists caused down-regulation of placental 
neurotransmitter receptors (23). Abnormalities or depletion of receptor sites, 
especially if the same process occurs in the fetal brain, could impair the function 
of the normal neonatal respiratory control network leading to frequent or 
prolonged apnea and subsequent IH.   
Many studies have assessed the impact of prenatal opioid exposure on 
sudden infant death syndrome (SIDS) in infants with controversial results. This 
study does not address SIDS; rather, it focuses on IH, the end result of apnea of 
prematurity. However, the mechanism by which prenatal opioid exposure is 
associated with increased SIDS and IH may be similar. Although our study period 
focused on the inpatient setting, it is plausible that opioid exposed infants 
continue to have increased cardiorespiratory events/IH after discharge. 
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Interestingly, compared to unexposed infants, opioid exposed infants had a trend 
toward longer length of stay (68 versus 85 days, p=NS), which may be related, in 
part, to persistent cardiorespiratory events. 
A major limitation of this study is that data related to exposure were 
retrospectively collected. Another limitation is a lack of reporting daily caffeine 
use and daily respiratory support settings. At our center, virtually all infants with 
GA less than 30 weeks are started on caffeine therapy. Furthermore, our study 
focused on IH events and lacked reporting of apnea and bradycardia events. 
Lack of addressing heart rate is a limitation since bradycardia events may be 
associated with poor long term outcomes (3). Another limitation is the small 
sample size; however, our sample size of isolated opioid exposure is relatively 
large compared to existing literature. This is a single center study; hence, our 
results may not be generalizable. Finally, we did not compare the long term 
neurodevelopmental outcomes for exposed versus unexposed infants.    
 
V. Conclusion 
 
There is rising evidence linking IH to neonatal morbidities and impairment. 
However, the exact threshold (frequency, duration, severity) by which IH leads to 
injury in preterm infants needs further investigation; i.e., any increase in IH may 
be associated with impairment in preterm infants. Furthermore, there is a need to 
understand factors, such as prenatal opioid exposure, that may influence IH and 
subsequently increase neonatal morbidities. In this study, we show an 
association between prenatal opioid exposure and increased IH measures in 
preterm infants. Studies to address the relationship between opioid exposures, 
IH, and long term neurodevelopmental outcomes are imperative. Given the rising 
epidemic of opioid misuse in the USA, understanding the relationship between 
opioid exposure, IH and long term impairment is imperative. A larger prospective 
study aimed at understanding these relationships may have a direct impact on 
short and long term management of preterm infants.  
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Table 3. 1: Baseline 
Characteristics 
Opioid Exposed Unexposed p-Value 
N=14 N=68 
Gestational age (weeks) 27.0 ± 2.1 27.0 ± 1.6 0.97 
Birth weight (grams) 948 ± 263 928 ± 247 0.79 
Male 6 (43%) 23 (34%) 0.54 
Apgar 5 min 7 (6, 7.5) 6 (5, 7) 0.21 
Prenatal steroids 12 (86%) 61 (91%) 0.62 
Mean ± SD, Median (Interquartile range) 
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Table 3. 2: Neonatal 
Morbidities and Outcomes 
 
Opioid  
Exposed 
Opioid 
Unexposed 
p-Value 
N=14 N=68 
Received Surfactant 14 (100%) 62 (91%) 0.58 
Respiratory distress syndrome 14 (100%) 67 (99%) 1 
Oxygen at 28 days of life 10 (71%) 39 (57%) 1 
Oxygen at 36 weeks corrected 
age 
7 (50%) 19 (28%) 0.26 
Oxygen at discharge 9 (64%) 30 (44%) 0.18 
Severe Bronchopulmonary 
Dysplasia 
9 (64%) 27 (46%) 0.21 
Postnatal steroids use for lung 
disease 
6 (43%) 19 (29%) 0.35 
Pneumothorax 1 (7%) 2 (3%) 0.43 
Patent Ductus Arteriosus 8 (57%) 24 (35%) 0.13 
Necrotizing Enterocolitis 0 (0%) 2 (3%) 1 
Late Onset Sepsis 
Mortality 
3 (21%) 
0 (0%) 
9 (13%) 
9 (13%) 
0.43 
0.35 
Length of Stay (days) 85 (59, 101) 68 (56, 91) 0.32 
Frequency (%), Median (Interquartile range) 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
 
Figure 3. 1: Flow diagram for patient eligibility. 
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Figure 3. 2: Comparison of %time-SpO2<80 between opioid exposed and 
unexposed. 
A) Preterm infants exposed to prenatal opioids had increased time spent with 
oxygen saturation less than 80% (%time-SpO2<80) compared to unexposed 
infants (p=0.03). The model adjusted for gestational age, birth weight, gender, 
prenatal steroids, and Apgar scores at 5 minutes of life. B) This figure 
demonstrates the estimated average %time-SpO2<80 medians in both groups 
calculated using the adjusted model results. Sqrt, square root. 
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Figure 3. 3: Comparison of IH-SpO2<80 between opioid exposed and 
unexposed. 
A) Preterm infants exposed to prenatal opioids did not have a significant increase 
in number of intermittent hypoxemia (IH) events per week (IH-SpO2<80) 
compared to unexposed infants (p=0.08). The model adjusted for gestational 
age, birth weight, gender, prenatal steroids, and Apgar scores at 5 minutes of 
life. B) This figure demonstrates the estimated average IH-SpO2<80 medians of 
opiate exposed versus unexposed preterm infants calculated using the adjusted 
model results.  Sqrt, square root 
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CHAPTER 4: INTERMITTENT HYPOXEMIA IS ASSOCIATED WITH 
INCREASED SERUM C-REACTIVE PROTEIN IN PRETERM INFANTS  
 
I. Introduction  
 
 Systemic inflammation perturbs breathing patterns, worsens apnea and 
cardiorespiratory events. There is ample evidence in preterm infants and animal 
models demonstrating that systemic inflammation increases apnea and 
subsequent IH (29, 30, 81-83). Furthermore, apnea and subsequent increase in 
IH is often an early sign of inflammatory processes such as sepsis and 
necrotizing enterocolitis (NEC) in the neonatal intensive care unit (NICU) (29, 
30, 81-83). However, interestingly, based on animal studies, the relationship 
between inflammation and IH may be bidirectional, Figure 4.1 (7). I.e. IH may 
be pro-inflammatory itself.  
 Mounting evidence, links IH with both short and long term neonatal 
morbidities such as retinopathy of prematurity, sleep disordered breathing, 
neurodevelopmental impairment and increased mortality (2, 3, 16, 45, 46, 54, 
55, 84-86). Intermittent hypoxemic episodes due to obstructive sleep apnea in 
adults are associated with increased levels of inflammatory biomarkers (87-93).  
Multiple inflammatory markers have been tested in adults. There is ample 
evidence demonstrating increased C-reactive protein (CRP) serum levels in 
adult patients with obstructive sleep apnea (87-93).  There are no studies in 
preterm infants to support IH being pro-inflammatory; however, there is rising 
evidence from neonatal animal models suggesting IH is pro-inflammatory. For 
example, IH exposed rat-pups had increased serum inflammatory biomarkers 
such as IFN-γ and IL-1β (32). Chronic IH in rodents increases inflammation 
(monocyte chemoattractant protein-1, IL1β, TNF-α, and a 5 fold increase in IL-6) 
in the carotid body chemoreceptors altering their function and subsequently 
affecting respiratory control and apnea (14, 33-35). We wanted to assess the 
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relationship between IH and serum CRP for the first time in human preterm 
infants.  
 
II. Methods 
 
Study Design and Data Collection 
Oxygen saturation (SpO2) data were prospectively collected from 26 
preterm infants less than 30 weeks gestational age (GA) admitted to our level 4 
NICU between November 2014 and September 2015. We used high resolution 
pulse oximeters (Radical 7: Masimo, Irvine, CA) set at 2 second averaging time 
and 1Hz sampling rate to continuously monitor patients. Pulse oximeters were 
equipped with serial data recorders (Acumen Instruments Corp) for continuous 
data collection. Novel programs were utilized to filter and analyze data (Matlab, 
Natick, MA) (1, 61). Data with artifacts were excluded. Only SpO2 data with good 
signal were included in the analyses. Infants with major congenital 
malformations were excluded. 
We collected blood samples at 30 days of life to assess for systemic 
inflammation at peak of IH. Blood samples for CRP were collected for research 
purposes and not for clinical purposes; i.e. not because there was a concern for 
illness or change in status. High sensitivity CRP was analyzed using commercial 
ELISA kits. Data related to other morbidities that may increase CRP such as 
sepsis and necrotizing enterocolitis (NEC) were collected. Other demographics, 
morbidities, and respiratory characteristics were collected from medical records.  
Statistical Analyses 
Average IH measures (IH profile) were calculated for the week prior to 
CRP collection. Plots of CRP and IH measures were performed to identify 
outliers. We assessed the relationship between IH and CRP using GraphPad 
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Prism 7. Statistical analyses were based on Pearson correlation and linear 
regressions. Since the exact threshold below which IH causes injury is 
unknown, we calculated an IH profile reflecting the continuum of the problem. 
We did not set a lower or upper limit for IH in this study. A drop in SpO2 to less 
than 80% is widely considered to be clinically relevant (1-3) and therefore was 
selected as the primary outcome measure. Other thresholds included SpO2 of 
85% and 90%. Furthermore, 6 different IH duration intervals were calculated: 1-
59 seconds, 60-119 seconds, 120-179 seconds, 180-239 seconds, 240-299 
seconds, more than or equal to 300 seconds.  
 
III. Results 
 
Of the 26 infants included, 25 had SpO2 data available during the week 
prior to CRP collection. Blood samples for CRP analyses were obtained at 
median day of life (DOL) 30 (IQR 29-32 days). Scatter plots identified 2 outliers 
with CRP values of 20.829mg/dL and 69.128mg/dL (Figure 4.2). One of the 
outliers had sepsis within 2 weeks (11 days) prior to the CRP collection date. 
Three other patients had sepsis but occurred more than 2 week prior to our 
assessment. No patients had NEC. Plots for IH measures to identify outliers are 
presented in Figures 4.3.  
Median GA is 27 weeks (Interquartile Range (IQR) 26 - 28 weeks). 
Median birth weight is 980 grams (IQR 763 - 1230 grams). There were no small 
for gestational age (SGA) infants. Median weight at the time of CRP is 1220 
grams (IQR 900 – 1440 grams). Median CRP is 0.236mg/dL (IQR 0.025 - 1.648 
mg/dL). Respiratory support data are presented in Table 4.1.  
There was strong positive correlation between our primary measure, 
%time-SpO2<80, and serum CRP levels (Figure 4.4). The positive correlation 
between percent time below threshold and CRP persisted with higher SpO2 
threshold of 85% and 90%. There was moderate positive correlation between our 
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primary measure, IH-SpO2<80, and serum CRP levels (Figure 4.5). The positive 
correlation between IH events and CRP persisted with higher SpO2 threshold of 
85%. There was a strong positive correlation between duration of events and 
CRP; i.e. the longer the IH events the higher the serum CRP (Figure 4.6). 
Furthermore, there was a statistically significant positive correlation between 
primary outcome IH measures and CRP at the 6 different duration intervals 
examined (except for IH-SpO2<80 at 1-59 seconds, p-Value 0.06) (Figures 4.7 
and 4.8). The mean SpO2 and CRP had a strong negative correlation; i.e. the 
lower the mean SpO2 the higher the inflammatory marker (Figure 4.9). There 
was no statistically significant correlation between IH mean nadir and CRP 
(Figure 4.10A). There was moderate negative correlation between peak mean IH 
and CRP as represented in Figure 4.10B.  
 
IV. Discussion 
 
Our results show that increased IH is associated with increased systemic 
CRP. This relationship between IH and inflammatory markers is documented for 
the first time in human preterm infants. Interestingly, most IH profile measures at 
all three thresholds and 6 duration categories correlated with worse inflammation. 
These results are clinically relevant as elevated inflammation during NICU stay, 
mainly 28 days, has been shown to be associated with worse long term 
outcomes (94). 
Intermittent hypoxemia at all thresholds and durations was associated with 
increased serum CRP. The strongest correlation was between %time-
SpO2<threshold and CRP. This is clinically relevant as percent time below 
threshold is available to the clinical team from the clinical pulse oximeter 
histograms. The frequency of IH correlated positively with CRP only with 
moderate and severe IH. The lower the mean SpO2 is the higher the serum 
CRP; an important finding with possible impact on the oxygen target saturation 
controversy in the NICU (2, 8, 37, 46, 95, 96).  
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C-reactive protein in comprised of five identical, non-covalently associated 
subunits (approximately 23 kD each) (97). C-reactive protein has both pro-
inflammatory and anti-inflammatory characteristics (98). Both acute and chronic 
inflammation can increase CRP such as infection and metabolic stresses, 
respectively (99, 100). We chose CRP as our inflammatory measure for multiple 
reasons. First, compared to other markers of inflammation, CRP is widely used in 
the NICU with known reference ranges (101-105). Second, CRP is a good and 
stable marker for low grade inflammation (100, 106). Minor CRP elevations are 
considered a marker of low-grade inflammation, sometimes called subclinical 
inflammation or mini-inflammation. Low grade inflammation is the degree of 
inflammation we expected will be associated with increased IH. We utilized high 
sensitivity CRP commercial ELISA kits in order to measure low grade CRP 
changes. Third, multiple adult studies including meta-analyses have 
demonstrated increased CRP in patients with IH from obstructive sleep apnea 
(87-93).  
Our results suggest that IH may be pro-inflammatory itself. Since IH is pro-
inflammatory, that may lead to a spiral or snowball effect (positive feedback 
loop). Apnea events cause IH and subsequent systemic postnatal inflammation 
that is transferred to the respiratory control network, peripheral chemoreceptors 
and lungs. The postnatal inflammation leads to a further cycle of increased 
apnea events and consequently higher frequency of IH (Figure 4.1). 
Interestingly, this phenomenon may be in part responsible for the IH peak at 4-5 
weeks of age (54). 
This study has multiple strength including the prospective design and 
novel results. A major limitation for this study is the small sample size. However, 
the results were consistent at multiple IH thresholds and duration intervals 
suggesting a significant relationship between IH and increased CRP.  Another 
limitation is the use of a single inflammatory marker. Future studies should focus 
on multiple inflammatory markers along the inflammation cascade. Other 
markers that have been associated with IH in adults with obstructive sleep apnea 
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or IH in neonatal rodent models include, Interleukin (IL)-6, IL-1β, IL-8, Tumor 
Necrosis Factor (TNF)-α, Intercellular Adhesion Molecule (ICAM)-1, Interferon 
(IFN)-γ, Vascular Cell Adhesion Molecule (VCAM)-1 (14, 32-35, 89).  
 We demonstrate in this study, for the first time in preterm infants, that IH is 
associated with increased inflammation, namely CRP. While there is mounting 
evidence of adverse effects of IH, there has been no focus on inflammation in the 
cycle of events in preterm infants. Our findings are significant as the increased 
inflammation may be the mediator for increased morbidities and impairment in 
infants with IH (2, 3, 16, 45, 46, 54, 55, 84-86). Future larger studies that 
examine the role of inflammation as a mediator for long term injury from IH 
should be examined.  
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Table 4. 1: Respiratory 
Characteristics 
                       Frequency, n (%) 
Room Air 3 (12%) 
Continuous Positive Airway 
Pressure 7 (28%) 
Non-Invasive Nasal Ventilation 6 (24%) 
Conventional Ventilation  9 (36%) 
Oxygen Supplementation 12 (48%) 
These respiratory setting were collected on the day of CRP measurement.  
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Figure 4. 1: Proposed vicious cycle related to apnea, IH and postnatal 
inflammation. 
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Figure 4. 2: Scatter plot for CRP levels in studied patient population  
Two outliers were identified. Arrows identify outliers. 
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Figure 4. 3: Scatter plots for IH in studied patient population. 
A) Frequency of IH. B) Percent time with SpO2 below threshold. C) Duration of 
IH. D) Mean, nadir and peak of IH. Arrows identify outliers. 
 
 
IH
-S
p O
2 <
9 0
 (>
4%
 D
ro
p )
IH
-S
p O
2 <
9 0
IH
-S
p O
2 <
8 5
IH
-S
p O
2 <
8 0
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
IH  F re q u e n c y  P lo ts
F
re
q
u
e
n
c
y
%
t im
e -
S p
O
2 <
9 0
 (>
4%
 D
ro
p )
%
tim
e -
S p
O
2 <
9 0
%
tim
e -
S p
O
2 <
8 5
%
tim
e -
S p
O
2 <
8 0
0
2 0
4 0
6 0
8 0
1 0 0
% tim e  P lo ts
P
e
rc
e
n
t
D u
ra
t io
n  
S p
O
2 <
9 0
 (>
4%
 D
ro
p )
D u
ra
t io
n  
S p
O
2 <
9 0
 
D u
ra
t io
n  
S p
O
2 <
8 5
D u
ra
t io
n  
S p
O
2 <
8 0
0
2 0
4 0
6 0
8 0
IH  D u ra tio n  P lo ts
S
e
c
o
n
d
s
S p
O
2  
M
e a
n
S p
o 2
 N
a d
ir
S p
O
2  
P e
a k
0
2 0
4 0
6 0
8 0
1 0 0
M e a n , N a d ir , P e a k  P lo ts
P
e
rc
e
n
t
←
←←
←
←
←
A
C D
B
 
55 
 
 
Figure 4. 4: Correlations comparing serum CRP and percent time below 
thresholds.  
A) %time-SpO2<90 (>4% Drop) versus CRP. B) %time-SpO2<90 versus CRP. 
C) %time-SpO2<85 versus CRP. D) %time-SpO2<80 versus CRP. All 
correlations were statistically significant with p-values were less than 0.01. 
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Figure 4. 5: Correlations comparing serum CRP and IH frequency. 
A) IH-SpO2<90 (>4% Drop) versus CRP. B) IH-SpO2<90 versus CRP. C) IH-
SpO2<85 versus CRP. D) IH-SpO2<80 versus CRP. The positive correlations 
between moderate (IH-SpO2<85), severe (IH-SpO2<80) IH and CRP are 
statistically significant (p-value less than 0.05). 
0 1 2 3 4 5
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
IH -S p O 2 < 9 0  (> 4 % )
C R P  (m g /d L )
IH
 F
re
q
u
e
n
c
y
0 1 2 3 4 5
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
IH -S p O 2 < 9 0
C R P  (m g /d L )
IH
 F
re
q
u
e
n
c
y
0 1 2 3 4 5
0
5 0 0
1 0 0 0
1 5 0 0
IH -S p O 2 < 8 5
C R P  (m g /d L )
IH
 F
re
q
u
e
n
c
y
0 1 2 3 4 5
0
2 0 0
4 0 0
6 0 0
8 0 0
IH -S p O 2 < 8 0
C R P  (m g /d L )
IH
 F
re
q
u
e
n
c
y
r  =  0 .1 8 0 6
(C I -0 .2 7 2 3  to  0 .5 6 8 )
p  =  0 .4 3 3 3
r  =  0 .1 5 1 6
(C I -0 .2 8 8 5  to  0 .5 3 8 8 )
p  =  0 .5 0 0 7
r =  0 .4 4 8 6
(C I 0 .0 3 3 2 4  to  0 .7 3 1 8 )
p  =  0 .0 3 6 3
r  =  0 .4 5 5 9
(C I 0 .0 3 0 1 5  to  0 .7 4 1 6 )
p  =  0 .0 3 7 8
A
B
C
D
 
57 
 
 
Figure 4. 6: Correlations comparing serum CRP and IH duration. 
A) Duration SpO2<90 (>4% Drop) versus CRP. B) Duration SpO2<90 versus 
CRP. C) Duration SpO2<85 versus CRP. D) Duration SpO2<80 versus CRP. All 
correlations were statistically significant with p-values were less than 0.0001. 
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G. CRP  versus 
%time-SpO2<80 
A 
(1-59s) 
B 
(60-119s) 
C 
(120-179s) 
D 
(180-239s) 
E 
(240-299s) 
F 
(≥300s) 
r 0.6215 0.5594 0.4713 0.6632 0.5861 0.4917 
95% CI 
0.2709 to 
0.8265 
0.1804 to 
0.7938 
0.062 to 
0.7449 
0.3353 to 
0.8477 
0.2185 to 
0.808 
0.0884 to 
0.7565 
p-Value 0.002 0.0068 0.0268 0.0008 0.0042 0.0201 
Figure 4. 7: Correlations comparing serum CRP and primary outcome 
measure %time-SpO2<80 at multiple duration intervals.  
A) 1-59 seconds B) 60-119 seconds C) 120-179 seconds D) 180-239 seconds E) 
240-299 seconds F) more than or equal to 300 seconds.  G) This table presents 
the correlation coefficients (r), 95% confidence intervals (CI) and p-values for all 
intervals. All correlations were statistically significant.   
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G. CRP versus 
IH-SpO2<80 
A 
(1-59s) 
B 
(60-119s) 
C 
(120-179s) 
D 
(180-239s) 
E 
(240-299s) 
F 
(300s ) 
r 0.4031 0.555 0.4671 0.6677 0.5819 0.57 
95% CI 
-0.02225 to 
0.7049 
0.1742 to 
0.7914 
0.05663 to 
0.7425 
0.3426 to 
0.85 
0.2124 to 
0.8058 
0.1954 to 
0.7995 
p-Value 0.0628 0.0073 0.0284 0.0007 0.0045 0.0056 
Figure 4. 8: Correlations comparing serum CRP and primary outcome 
measure IH-SpO2<80 at multiple duration intervals. 
A) 1-59 seconds B) 60-119 seconds C) 120-179 seconds D) 180-239 seconds E) 
240-299 seconds F) more than or equal to 300 seconds.  G) This table presents 
the correlation coefficients (r), 95% confidence intervals (CI) and p-values for all 
intervals. All correlations (except 1-59 seconds) were statistically significant.   
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Figure 4. 9: Negative correlation between mean SpO2 and serum CRP. 
The lower is the mean oxygen saturation to the higher the CRP level. 
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Figure 4. 10: Correlation between serum CRP and IH mean nadir/mean peak 
 A) Correlation between CRP and IH mean nadir. There was no statistically 
significant relationship. B)  Significant negative correlation between mean peak 
SpO2 and CRP.  
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CHAPTER 5: MATERNAL CHORIOAMNIONITIS AND INTERMITTENT 
HYPOXEMIA IN PRETERM INFANTS 
 
I. Introduction 
 
Four million babies are born per year in the United States and close to a 
half million are premature (<37 weeks gestation) (107). The total societal 
economic cost of preterm birth is estimated at 26 billion dollars (108-110). Mean 
costs of care associated with extreme prematurity are nearly a quarter of a 
million dollars in the first 4 years of life; approximately 20 times higher than late 
preterm infants (111). Although significant progress has been made in the care of 
preterm infants, they continue to suffer from significant morbidities such as 
apnea, chronic lung disease (bronchopulmonary dysplasia (BPD)), retinopathy of 
prematurity (ROP), and neurodevelopmental impairments (NDI) (112, 113). 
Intermittent Hypoxemia (IH), contributes to the aforementioned morbidities (54). 
Brief episodes of oxygen desaturations may seem clinically insignificant, but 
these IH episodes, occurring up to hundreds of events/day, have a cumulative 
effect on morbidities and mortality. As presented in Chapter 1, mounting 
evidence, links IH with both short and long term neonatal morbidities such as 
ROP, NDI, sleep disordered breathing, and increased mortality (2, 3, 16, 45, 46, 
54, 55, 84-86). Laboratory and animal data show IH results in increased 
inflammatory cytokines, increased free radicals and oxidative stress, increased 
white matter injury, neurocognitive handicap, and poor growth (4, 41, 54, 114-
120).  
 Several predictors that influence IH have been investigated. Gestational 
age and IH are inversely related (5); with extremely preterm infants having the 
highest prevalence of IH. Infants with BPD have increased IH that persists on 
mechanical ventilation (1, 2, 7). Preterm infants with anemia are at increased 
risk for IH (1, 36); as hematocrit level decreases the probability of apnea/IH 
events increases. Intermittent hypoxemia natural progression changes with 
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postnatal age. There is low IH frequency during the 1st week of life, followed by 
a progressive increase over weeks 2-3, peaks around 4-5 weeks, and 
decreases at weeks 6-8 (1, 2, 54). The reasons leading to the rise in IH 
postnatally are poorly defined but likely due to both developing lung disease and 
chemoreceptor dysregulation possibly due to inflammation and hypoxia (7). 
Systemic inflammation increases apnea events and subsequently IH (29). 
Hofstetter et al. showed that systemic inflammation increased IL-1β that binds to 
its receptors located on endothelial cells of the blood brain barrier (29). Activation 
of IL-1β receptors leads to increased prostaglandins in the respiratory control 
network in the brain leading to respiratory depression/apnea and subsequent IH 
(29, 121). In addition, systemic inflammation worsens lung disease, decreases 
lung reserves leading to more IH in the presence of apnea (16). Interestingly, 
inflammation in the pulmonary system can be transmitted, likely through the 
vagal nerve, to the central respiratory network in the brain stem leading to further 
respiratory instability/apnea (30, 31, 122). In summary, inflammation increases 
apnea, worsens lung disease and subsequently increases IH. 
Prenatal (intrauterine) inflammation is a common cause of preterm birth. 
Prenatal inflammation can happen with or without infection. Recently in 2016 the 
National Institute of Child Health and Human Development (NICHD) suggested 
the Triple I terminology referring to Intrauterine Inflammation, Infection or both in 
order to replace chorioamnionitis. For the purpose of consistency in this 
document, we will use the terminology of maternal chorioamnionitis (MC) as the 
main contributor to prenatal inflammation (123). Funisitis is inflammation of the 
umbilical cord (124). The majority of fetuses exposed to MC develop a systemic 
fetal inflammatory response syndrome (FIRS), usually defined as elevated serum 
interleukin-6 (IL-6). Fetal inflammatory response syndrome occurs due to the 
infant being in direct contact with affected amniotic fluid and/or inflammatory cell 
or cytokine transfer through placental circulation (125-127). Importantly, prenatal 
inflammation is reported to be a major contributor to morbidities e.g. apnea, BPD, 
ROP and brain injury (2, 127-150).  
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Pilot Assessment 
 A total of 30 infants less than 30 weeks GA were enrolled in this pilot trial 
to test the hypothesis that prenatal inflammation is associated with increased IH 
in postnatal life. Patients were monitored for 4 weeks. The presence of MC was 
collected from medical records through our Vermont Oxford Network (VON) 
database. Maternal chorioamnionitis as documented by the clinical team was 
considered positive in the data base. Blood samples were collected on day of life 
(DOL) 1 to measure high-sensitivity C-reactive protein (hsCRP); widely used in 
the NICU and a reliable measure of low grade inflammation (106, 151-154). Data 
related to MC and blood samples were available for 26 patients and, of those, 6 
patients had MC. Median hsCRP on DOL 1 was more than 10 times greater in 
patients with MC (0.82 mg/dl) compared to no MC (0.071mg/dl), however, these 
differences were not statistically significant. Patients with MC had statistically 
significant increased IH during the study period (Figure 5.1) that persisted after 
adjusting for GA, gender, ethnicity, and severity of disease (SNAP-PE) scores.  
A limitation of the pilot assessment was that MC was collected per the 
clinical team and may not meet all clinical chorioamnionitis criteria (123). Hence, 
we decided to define MC in the following study per placental pathology reports. 
We wanted to test the hypothesis that pathologic MC or funisitis are associated 
with increased IH in preterm infants. Since in funisitis, the umbilical cord is 
affected, we hypothesized a greater impact on IH in those infants.  
 
II. Methods 
Study Design and Data Collection 
Oxygen saturation data were prospectively collected from preterm infants 
less than 35 weeks gestational age (GA) admitted to our level 4 NICU between 
November 2014 and July 2017. We used high resolution pulse oximeters 
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(Radical 7: Masimo, Irvine, CA) set at 2 second averaging time and 1Hz 
sampling rate to continuously monitor patients during the first 4 weeks of life. In 
order to differentiate intermittent from sustained hypoxemia, we included events 
between 4-180 seconds (1). The exact threshold below which IH is clinically 
significant is controversial. A drop in SpO2 to less than 80% is widely 
considered to be clinically relevant (1-3). Therefore, the primary outcome 
measures were defined as percent time spent with SpO2 below 80% (%time-
SpO2<80) and frequency of IH events with SpO2 drop below 80% (IH-
SpO2<80).  
Pulse oximeters were equipped with serial data recorders (Acumen 
Instruments Corp) for continuous data collection. Novel programs were utilized 
to filter and analyze data (Matlab, Natick, MA) (1, 61). Data with artifacts were 
excluded. Only SpO2 data with good signal were included in the analyses. 
Preterm infants less than 30 weeks GA were included. Infants with major 
congenital malformations were excluded.  
 The presence of MC was collected from medical records. We chose our 
exposure as pathologic MC (inflammation noted in the placenta on pathology 
reports) or Funisitis (inflammation of the umbilical cord on pathology reports) in 
attempt to have more objective data. We did not include clinical MC since the 
data related to MC was collected retrospectively and hence clinical parameters 
may not be always appropriately documented.   
 Severe BPD was investigated as a secondary outcome measure given 
the controversial literature suggesting a relationship between MC and BPD. 
Severe BPD was defined per the National Institute of Child Health and Human 
Development (NICHD) criteria for respiratory status at 36 weeks corrected age 
(155). Respiratory settings and other demographic and baseline characteristics 
were collected from medical charts.  
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Statistical Analyses  
Descriptive statistics for continuous variables are presented as either the 
mean with standard deviation or median with interquartile range (IQR), and 
frequencies and percentages are given for categorical variables.  Two-sample t-
tests and Wilcoxon two-sample tests were used to compare MC or Funisitis 
exposed to those not exposed with respect to continuous variables, and chi-
square or Fisher’s exact tests were used for categorical variables.  Patients with 
exposure or MC or Funisitis were compared to unexposed. In addition, infants 
with MC only and Funisitis were separately compared to unexposed. To 
compare MC or Funisitis infants to those not exposed with respect to IH 
measures over time, we utilized multivariate Gaussian linear modeling in order 
to account for repeated measurements from subjects, and to adjust for the 
potential confounders of gestational age, small for gestational age (SGA) and 
the use of prenatal steroids.  In order to meet statistical assumptions in these 
models, the square root of the IH measures was taken. Furthermore, weekly 
observations were weighted by the percentage of time IH was tracked during the 
given week.  Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, 
N.C.) and GraphPad Prism. 
 
III. Results 
 
A total of 151 patient included in our cohort were reviewed. Of those, 121 
infants had placental pathology reports and respiratory/IH outcomes data. 
Baseline characteristics and comparisons between groups are presented in 
Tables 5.1 - 5.4. There was a difference in GA (p <0.0001) and birth weight (p= 
0.0019) among groups. Deaths prior to discharge varies among groups 
(p=0.0011) with increased mortality in the exposed compared to unexposed 
infants. Other baseline characteristics did not vary among groups. 
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Contrary to our hypothesis, infants with funisitis had no major differences 
in IH measures compared to unexposed (Figures 5.1 and 5.3). The differences 
were most pronounced while comparing the MC only group versus unexposed 
(Figures 5.2 and 5.4).  After adjusting for GA, SGA and prenatal steroids, 
statistically significant differences were noted while comparing the MC only 
versus unexposed (Figures 5.3 and 5.5). Severe BPD tended to be higher in 
any of the exposed groups compared to unexposed; however both unadjusted 
and adjusted differences were not statistically significant (Figure 5.6) 
 
IV. Discussion 
 
Our results related to IH measures in infants exposed to perinatal 
inflammation were inconsistent. The significant increase in IH in infants with 
clinical MC noted in our pilot study was not consistently replicated in infants with 
pathologic definition of MC. There were increased IH measures in infants 
exposed to pathologic MC and/or funisitis compared to unexposed infants. After 
adjusting for GA, SGA status and prenatal steroids, differences were statistically 
significant in the MC only group. Severe BPD did not vary among groups, 
however tended to be higher in pathologic MC and/or funisitis exposed infants 
compared to unexposed.   
 There were no differences in SGA status between groups, a major risk 
factor for increased IH. Infants with pathologic MC had lower GA and birth 
weight compared to those unexposed. This is an expected finding given that the 
incidence of prenatal inflammation is inversely related to GA, ranging from 75% 
to 35% in 23 and 29 week GA infants respectively (127, 156-159). This 
difference in GA may be responsible for the increased unadjusted IH in the 
exposed groups. Statistically significant higher IH persisted in the MC only group 
after adjusting for GA. Interestingly, infants with MC only group had a 
statistically significant smaller GA compared to funisitis infants (Table 4). This 
 
68 
 
may suggest that the impact of MC on IH is most pronounced in extreme 
prematurity; in contrast to our cohort that included older preterm infants of less 
than 35 weeks GA. We did not adjust for birth weight in the model analyses 
given the collinear relationship with GA.  
Our results suggest that the effect of prenatal inflammation due to MC on 
IH persisted far beyond the perinatal period; an interesting and important finding 
documented for the first time in human preterm infants. The reasons for 
persistently increased IH in MC exposed infants at 5-6 weeks postnatal age 
(Figure 5.1 and Figure 5.3) are unknown. We speculate that perinatal 
inflammation from MC exacerbates the IH/inflammation cycle by causing 
chemoreceptor dysregulation and worsening of lung disease (Figure 5.7) (7).  
A limitation of this study is that data related to MC were retrospectively 
collected. The choice of pathologic definition of chorioamnionitis is another 
limitation that likely had an impact on our results. Pathologic chorioamnionitis is 
a histologic finding that may not be symptomatic with no change in maternal 
clinical status and subsequently the infant. The placenta is thought to act as a 
barrier that protects the infant and therefore without clinical symptoms the full 
impact of inflammation may not have reached the infant. Our choice of 
pathologic definition relates to inconsistent documentation in medical records of 
symptoms of clinical chorioamnionitis such as uterine tenderness and foul 
smelling amniotic fluid; hence we may underestimate the number of clinical 
chorioamnionitis. The secondary outcome measure of severe BPD was chosen 
as a dichotomous variable per the NICHD definition (155). The absence of 
significant differences in severe BPD among groups may under estimate the 
complexity and continuum of lung disease in preterm infants. Finally, this is a 
single center study and our results may not be generalizable. 
 This study investigates relationship between prenatal inflammation due to 
MC and IH. No other groups have studied this relationship in the past in preterm 
infants. We demonstrated a persistently increased IH in the MC only group 
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beyond the perinatal period, long after the direct effect of inflammation resolves. 
Our inconsistent results may be related to the pathologic definition of MC versus 
clinical chorioamnionitis. Prospective studies investigating the impact of clinical 
chorioamnionitis on IH may provide mechanistic insights in this understudied 
relationship between inflammation and IH in preterm infants. 
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Table 5. 1: Baseline Characteristics for All Infant with and without MC or 
Funisitis 
 
No MC or Funisitis MC or Funisitis p-Value 
N 58 61 
 
Gestational Age 27 3/7 25 6/7-28 5/7 25.6 24 6/7-26 6/7 <0.0001 
Birth Weight 1030 765-1155 830 685-980 0.006 
Small for Gestational Age 3 5.2% 3 4.9% 1 
Prenatal Steroids 53 91.4% 54 88.5% 1 
Female 28 48.3% 31 50.8% 0.31 
Non-Hispanic/ White 49 84.5% 52 85.2% 1 
Deaths 2 3.4% 8 13.1% 0.001 
Median IQR, n %, MC: Maternal Chorioamnionitis 
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Table 5. 2: Baseline Characteristics for No MC or Funisitis versus MC only infants 
 
No MC or Funisitis MC only p-Value 
N 58 19 
 
Gestational Age 27 3/7 25 6/7-28 5/7 25 1/7 23 6/7-25 6/7 <0.0001 
Birth Weight 1030 765-1155 730 640-853 0.001 
Small for Gestational Age 3 5.2% 1 5.3% 1 
Prenatal Steroids 53 91.4% 16 84.2% 1 
Female 28 48.3% 6 31.6% 0.4253 
Non-Hispanic/ White 49 84.5% 17 89.5% 0.7893 
Deaths 2 3.4% 4 21.1% 0.0263 
Median IQR, n %, MC: Maternal Chorioamnionitis 
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Table 5. 3: Baseline Characteristics for No MC or Funisitis versus Funisitis 
exposed 
 
No MC or Funisitis Funisitis p-Value 
N 58 42 
 
Gestational Age 27 3/7 25 6/7-28 5/7 26 2/7 25 1/7-27 5/7 0.0093 
Birth Weight 1030 765-1155 880 700-1145 0.1047 
Small for Gestational Age 3 5.2% 2 4.8% 1 
Prenatal Steroids 53 91.4% 38 90.5% 0.0067 
Female 28 48.3% 25 59.5% 0.0558 
Non-Hispanic/ White 49 84.5% 35 83.3% 0.7069 
Deaths 2 3.4% 4 9.5% 0.1829 
Median IQR, n %, MC: Maternal Chorioamnionitis 
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Table 5. 4: Baseline Characteristics for Infant with MC versus Funisitis 
 
MC Funisitis p-Value 
N 19 42  
Gestational Age 25 1/7 23 6/7-25 6/7 26 2/7 25 1/7-27 5/7 0.003 
Birth Weight 730 640-853 880 700-1145 0.03 
Small for Gestational Age 1 5.3% 2 4.8% 1 
Prenatal Steroids 16 84.2% 38 90.5% 0.69 
Female 6 31.6% 25 59.5% 0.19 
Non- Hispanic/ White 17 89.5% 35 83.3% 1 
Deaths 4 21.1% 4 9.5% 0.47 
Median IQR, n %,  MC: Maternal Chorioamnionitis 
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Figure 5. 1:  Increase in %time-SpO2<80 in preterm infants less than 30 
weeks born with maternal chorioamnionitis (MC). 
The %time spent with SpO2<80% was higher in the MC group compared to no 
MC. Statistically significant difference noted in model analysis (adjusted) 
between groups during study period, p<0.05. This data is from a pilot 
assessment defining MC per clinical team.  
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Figure 5. 2: Unadjusted differences in %time-SpO2<80 between pathologic 
maternal chorioamnionitis (MC) and/or Funisitis versus unexposed 
This figure demonstrates unadjusted differences in %time-SpO2<80 between 
pathologic maternal chorioamnionitis (MC) and/or Funisitis and unexposed (no 
MC or Funisitis). A) The %time-SpO2<80 was higher in MC or funisitis group 
compared to no MC or funisitis (unexposed). The differences were statistically 
significant during postnatal weeks 4, 5, 6, and 8. B)  The %time-SpO2<80 was 
consistently higher in MC only compared to no MC or funisitis. The differences 
were statistically significant during all postnatal weeks (except week 2). C) There 
were no statistically significant differences in %time-SpO2<80 in funisitis vs no 
MC or funisitis groups. **p<0.01, *p<0.05, +p<0.1. 
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Figure 5. 3: Adjusted differences in %time-SpO2<80 between pathologic MC 
and/or Funisitis versus unexposed 
This figure demonstrates adjusted differences in %time-SpO2<80 between 
pathologic maternal chorioamnionitis (MC) and/or Funisitis and unexposed (no 
MC or Funisitis). The graphs presents exposed minus unexposed estimates after 
adjusting for gestational age, small for gestational age status and prenatal 
steroids. A) There was no difference in %time-SpO2<80 in MC or funisitis group 
compared to no MC or funisitis (unexposed). B)  The %time-SpO2<80 was 
higher in MC only compared to no MC or funisitis. The adjusted differences were 
statistically significant during postnatal weeks 5 and 6. C) There were no 
statistically significant differences in %time-SpO2<80 in funisitis vs no MC or 
funisitis groups. *p<0.05, +p<0.1. 
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Figure 5. 4: Unadjusted differences in IH-SpO2<80 between pathologic MC 
and/or Funisitis versus unexposed 
This figure demonstrates unadjusted differences in IH-SpO2<80 between 
pathologic maternal chorioamnionitis (MC) and/or Funisitis and unexposed (No 
MC or Funisitis). A) There was a trend toward higher IH-SpO2<80 in MC or 
funisitis group compared to no MC or funisitis (unexposed) that was statistically 
significant during postnatal weeks 6 and 8. B)  There was a trend toward higher 
IH-SpO2<80 in MC only compared to no MC or funisitis. The differences were 
statistically significant during postnatal weeks 1, 6 and 8. C) There was a trend 
toward higher IH-SpO2<80 in funisitis vs no MC or funisitis groups that reached 
statistical significance during week 6 only. **p<0.01, *p<0.05, +p<0.1. 
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Figure 5. 5: Adjusted differences in IH-SpO2<80 between pathologic MC 
and/or Funisitis and unexposed (no MC of funisitis) 
This figure demonstrates adjusted differences in IH-SpO2<80 between 
pathologic maternal chorioamnionitis (MC) and/or Funisitis and unexposed (no 
MC or Funisitis). The graphs presents exposed minus unexposed estimates after 
adjusting for gestational age, small for gestational age status and prenatal 
steroids. A) There was no difference in IH-SpO2<80 in MC or funisitis group 
compared to no MC or funisitis (unexposed). B)  There was no difference in IH-
SpO2<80 in MC only compared to no MC or funisitis. C) There were no 
significant differences in IH-SpO2<80 in funisitis vs no MC or funisitis groups. 
+p<0.1. 
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Figure 5. 6: Differences in severe bronchopulmonary dysplasia (BPD) 
among groups 
This figure presents the frequency on severe bronchopulmonary dysplasia (BPD) 
among groups. There was a trend towards increased severe BPD in the MC 
and/or Funisitis groups compared to unexposed (No MC or Funisitis); MC or 
Funisitis p=0.14, MC p=0.057, funisitis p= 0.42. A logistic regression model 
adjusting for gestational age, small for gestational age status and prenatal 
steroids showed no a statistically significant difference in severe BPD among 
groups (p=0.79). 
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Figure 5. 7: Proposed relationship between intermittent hypoxemia and 
inflammation and possible role of maternal chorioamnionitis.  
The relationship between IH and inflammation is bidirectional with inflammation 
worsening IH and subsequently IH increases inflammation leading to further 
respiratory depression. Prenatal inflammation (maternal chorioamnionitis) 
exacerbates the cycle leading to more IH.  
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CHAPTER 6: ROLE OF INDOMETHACIN IN REDUCING INTERMITTENT 
HYPOXEMIA: PRELIMINARY ASSESSMENT 
 
 
I. Introduction 
 
Although significant progress has been made in the care of preterm infants, 
they continue to suffer from significant morbidities such as apnea, 
bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and 
neurodevelopmental impairments (NDI) (112, 113). In addition, prematurity is 
associated with elevated societal economic costs.  Four million babies are born 
per year in the United States and close to a half million are premature (107) with 
total societal economic cost of approximately 26 billion dollars (108-110). Mean 
costs of care associated with extreme prematurity are nearly a quarter of a 
million dollars in the first 4 years of life; approximately 20 times higher than late 
preterm infants (111).  
Intermittent Hypoxemia (IH), episodic drops in oxygen saturations, 
contributes to the aforementioned morbidities (54). Brief episodes of oxygen 
desaturations may seem clinically insignificant, but these IH episodes, occurring 
up to hundreds of events/day, have a cumulative effect on morbidities and 
mortality. Mounting evidence, links IH with both short and long term neonatal 
morbidities such as retinopathy of prematurity (ROP), neurodevelopmental 
impairment (NDI), sleep disordered breathing, and increased mortality (2, 3, 16, 
45, 46, 54, 55, 84-86). Laboratory and animal data show IH results in increased 
inflammatory cytokines, increased free radicals and oxidative stress, increased 
white matter injury, neurocognitive handicap, and poor growth (4, 41, 54, 114-
120). Decreasing IH will lead to decreased associated morbidities and 
impairment in preterm infants. In addition since cardiorespiratory events delay 
discharge (6, 160), an intervention to decrease IH will reduce length of stay and 
the burden on health care dollars. 
 
82 
 
Currently there are multiple strategies aimed at decreasing IH. Those 
mainly include methyl xanthine use and respiratory support; i.e. focus on 
treatment of apnea and management of lung disease. Although effective, the 
aforementioned strategies do not eliminate IH or lead to lung injury with 
subsequent long term consequences (4, 161-175). No current strategy focus on 
other causes of increased IH such as inflammation. Since prenatal inflammation 
plays a role in increased IH, finding strategies to ameliorate prenatal/perinatal 
inflammation may be effective at decreasing IH and associated morbidities. 
Preterm infants are commonly born through a prenatal inflammatory process 
(123, 151, 176, 177). The increased systemic inflammation at birth worsens 
apnea and lung disease leading to a rise in IH. Anti-inflammatory agents may 
ameliorate systemic inflammation and decrease IH. Olsson et al. in rat pup 
experiments showed that indomethacin reversed the depressive respiratory 
effects of inflammation (caused by IL-1 β and lipopolysaccharide (LPS)) in 
addition to hypoxia (144). In this preliminary assessment, we wanted to assess 
the effect of indomethacin, anti-inflammatory agent, on IH in preterm infants.  
 
II. Methods 
Study Design and Data Collection 
Oxygen saturation data were prospectively collected from 30 preterm 
infants less than 30 weeks gestational age (GA) admitted to our level 4 NICU 
between November 2014 and September 2015. We used high resolution pulse 
oximeters (Radical 7: Masimo, Irvine, CA) set at 2 second averaging time and 
1Hz sampling rate to continuously monitor patients during the first 4 weeks of 
life. In order to differentiate intermittent from sustained hypoxemia, we included 
events between 4-180 seconds (1). The exact threshold below which IH is 
clinically significant is controversial. A drop in SpO2 to less than 80% is widely 
considered to be clinically relevant (1-3). Therefore, the primary outcome 
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measure was defined as percent time spent with SpO2 below 80% (%time-
SpO2<80).  
Pulse oximeters were equipped with serial data recorders (Acumen 
Instruments Corp) for continuous data collection. Novel programs were utilized 
to filter and analyze data (Matlab, Natick, MA) (1, 61). Data with artifacts were 
excluded. Only SpO2 data with good signal were included in the analyses. 
Infants with major congenital malformations were excluded.  
Infants were randomized to placebo versus indomethacin in this 
randomized controlled (double blind) trial (RCT). Indomethacin was given within 
12 hours of birth and repeated every 24 hours for a total of 3 doses per the 
current evidence based dosing regimen utilized for other indications (178-183). 
Neonatal morbidities, including maternal chorioamnionitis (MC), were collected 
from medical records. In regards to this assessment, after the intervention 
infants received the standard clinical care per clinical team; except for the 
additional pulse oximeter. 
Statistical Analyses   
Statistical analyses for IH were based on linear mixed models, which 
statistically accounted for repeated measures. Intermittent hypoxemia (%time-
SpO2<80) and change of IH over time were compared in indomethacin versus 
placebo groups using SAS version 9.4 (SAS Institute, Cary, N.C.). Analyses 
were based on intention-to-treat, and tests were two-sided with a 5% 
significance level.  Comparisons were performed for all infants and in infants 
with MC only; as we considered the latter most likely group to benefit given they 
are born through and inflammatory process. Comparisons for baseline 
characteristics, respiratory support and morbidities were performed using 
GraphPad Prism 7 (GraphPad Software, La Jolla California USA).  
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III. Results 
 
Oxygenation data was available on 26 preterm infants with 13 infants 
each of the indomethacin and placebo groups. Table 1 represents baseline 
characteristics between indomethacin and placebo groups. There were no 
differences in GA, birth weight and gender and other baseline characteristics 
(Table 6.1). Table 2 represents respiratory characteristics during and at the end 
of study period showing no significant differences between groups. More infants 
were on non-invasive support at 36 weeks corrected age, however these results 
were not statistically significant (Table 6.2).  
There were no statistically significant differences in neonatal morbidities 
between groups as represented in Table 6.3. There was one death in the 
indomethacin group versus none in placebo. Severe IVH was similar in both 
groups. Infants in the placebo group tended to have more PDA, however, all 
except for one were non-hemodynamically significant per Gomez et al (61). Late 
onset sepsis and necrotizing enterocolitis rates were not different between 
groups.  
Although results were not statistically significant, there was a trend 
toward lower IH rates in the indomethacin compared to placebo group. Figure 
6.1 presents data for all infants. Figure 6.2 presents data from the patients born 
with MC. There is attenuation of the peak %time-SpO2<80 at 4-5 weeks of life, 
however it was not statistically significant. 
 
IV. Discussion 
 
This preliminary data demonstrate that indomethacin, administered 
shortly after birth, may be a promising new therapy for reducing IH in preterm 
infants. Infants with increased prenatal inflammation due to MC may benefit the 
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most from this intervention. Perinatal inflammation plays a major role in the 
pathophysiology of IH and vice versa; and administering an anti-inflammatory 
agent may break the IH/inflammation vicious cycle in its earliest stages leading 
to decreased IH (Figure 6.3).  
Current strategies aimed at decreasing IH focus on treatment of apnea 
and management of lung disease. Caffeine, a competitive adenosine receptor 
inhibitor, improves IH (4, 161, 162). Recent evidence suggest that caffeine may 
also have mild anti-inflammatory effects (184). Caffeine is used in NICUs 
worldwide and usually discontinued around 34-36 weeks corrected age (185). 
Recently, Rhein et al. showed that prolonged caffeine use reduces IH frequency 
until 37 weeks corrected age. Although caffeine is effective in decreasing IH, it 
does not eliminate IH. Other approaches to ameliorate IH are respiratory support 
measures such as mechanical ventilation, continuous positive airway pressure 
(CPAP) and oxygen supplementation (13, 186). However, respiratory support, 
even with current gentle ventilation strategies, leads to lung injury with 
subsequent long term consequences (163-174). In addition, oxygen 
supplementation in preterm infants leads to ROP (major cause of visual 
impairment) (37). Furthermore, preterm infants continue to have frequent IH 
events while on respiratory support (1, 2). A strategy that addresses other factors 
that increases IH (such as inflammation) may have an additive impact on 
amelioration of IH and hence improve long term outcomes. Although our results 
are not statistically significant, our trends align with preclinical animal model data. 
Olsson et al., demonstrated that indomethacin administration reversed the 
depressive effects of inflammation on breathing patterns(144).  Indomethacin is a 
promising intervention that needs further investigation. Finding a strategy 
(indomethacin) to decrease inflammation at birth may decrease IH and 
subsequently decrease associated morbidities in preterm infants. 
Prophylactic indomethacin has been tested in preterm infants to reduce 
other neonatal morbidities such as IVH and PDA. Multiple studies demonstrated 
that indomethacin decreases severe IVH by more than 30% (183, 187). 
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However, the decrease in IVH did not translate to improved long term outcomes 
(187). Similarly prophylactic indomethacin use improves PDA closure (179, 
188). However, prophylaxis was not more effective, compared to early treatment 
of symptomatic PDA, at reducing mortality and respiratory outcomes (189). Both 
the lack of long term benefit and increased risk benefit ratio, especially in infants 
without PDA, led to increased practice variation in use of prophylactic 
indomethacin. However, indomethacin has not been prospectively studied in 
preterm infants born with MC. Since these infants are born through an 
inflammatory process, we speculate they may benefit the most from an anti-
inflammatory agent. As shown in Figure 6.2, infants with MC who received 
indomethacin tended to have lower IH peak at 1 month of life. 
For future larger RCT involving infants with MC, indomethacin should be 
considered for multiple reasons. First, in contrast to postnatal steroids, 
indomethacin has a good safety profile and is not associated with long term NDI 
in preterm infants (178, 180, 190-194). Adverse effects associated with 
indomethacin include transient renal insufficiency (195); which can be 
ameliorated by interventions to improve renal perfusion. Other reported but rare 
adverse effects include increased risk of bleeding and intestinal perforation 
(178, 180, 191, 193, 194). Second, indomethacin is associated with decreased 
morbidities, mainly patent PDA and IVH (178-180, 192, 196, 197); morbidities 
that may affect cardiorespiratory events in preterm infants. Third, indomethacin 
also regulates blood flow to the brain which may lead to improved respiratory 
control and less IH (another mechanism to improve IH); as preterm infants have 
a paradoxical ventilatory depression in response to hypoxia/poor brain perfusion 
(198, 199). Fourth, indomethacin is an effective anti-inflammatory agent that 
reversibly inhibits cyclooxygenase (COX)-1 and COX-2 enzymes, which results 
in decreased formation of prostaglandin precursors; main culprits leading to 
apnea in the setting of inflammation (29, 30). Fifth, animal data show 
indomethacin reverses the effects of inflammation on respiratory patterns(144). 
Sixth, indomethacin is not the standard of care with wide practice variation both 
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locally and nationally creating equipoise and ability to test indomethacin (200). 
Finally, although indomethacin has been studied in preterm infants, the focus of 
those studies was not in the setting of perinatal inflammation or IH.  
A major limitation of this study is the small sample size especially for the 
subset involving MC patients. However, this was a preliminary assessment 
aimed at generating pilot data to power future larger studies. Another limitation 
of this study is the use of indomethacin dosing regimen for IVH and PDA 
prophylaxis (179, 181-183). Indomethacin was administered in 3 doses 
(0.2mg/kg/dose on DOL1 and 0.1mg/kg/dose on DOL 2 and 3) in the first 3 days 
of life. This dosing regimen has documented safety but it may not be adequate 
to suppress inflammation in infants with born with MC. Longer treatment course 
may be necessary to have a significant impact on decreasing inflammation and 
subsequent IH. Ideally, pre and post indomethacin inflammatory markers should 
have been measured to document a decrease in systemic inflammation.  
 This is the first study to test the effect of indomethacin in management of 
IH in preterm infants. This innovative pilot study possibly identified a subset of 
preterm infants (with prenatal inflammation/MC) who may benefit the most from 
indomethacin to reduce IH; an important discovery in the era of precision 
medicine. Future larger studies should focus on investigating indomethacin in 
patients born with MC. 
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Table 6. 1: Baseline 
Characteristics 
Indomethacin Placebo 
p-Value 
N=13 N=13 
    
Gestational age, weeks 27 4/7 (26 2/7-28 
5/7) 
27 3/7 (25 3/7-28 
5/7) 
NS 
Birth weight, grams 980 (750 - 1228) 1080 (735 - 1230) NS 
Male 69.2% 69.2% NS 
Apgar 5 min 5 (3-7) 6 (5-8) NS 
Maternal Chorioamnionitis 2 (15.4%) 4 (30.8%) NS 
Prenatal steroids 13 (100%) 12 (92.3%) NS 
Frequency (%), Median (Interquartile range) 
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Table 6. 2: Respiratory Characteristics 
Indomethacin Placebo 
p-Value 
N=13 N=13 
    
Respiratory distress syndrome 13 (100%) 13 (100%) NS 
Received Surfactant 12 (92%) 11 (85%) NS 
 
Respiratory Support at 28 days of life                                                        NS 
Oxygen Supplementation 11 (84.6%) 12 (92.3%)  
No Support 1 (7.7%) 1 (7.7%)  
Non Invasive Support 8 (61.5%) 7 (53.8%)  
Ventilator Support 4 (30.8%) 5 (38.5%)  
 
Respiratory Support at 36 weeks corrected age (CA)                               NS 
Oxygen Supplementation 9 (69.2%) 6 (46.2%)  
No Support 0 (0%) 6 (46.2%)  
Non Invasive Support 9 (69.2%) 5 (38.5%)  
Ventilator Support 1 (7.7%) 1 (7.7%)  
Discharged/Death prior 36 weeks CA 2 (15.4%) 1 (7.7%) 
 
 
Oxygen at discharge 7 (54%) 6 (46%) NS 
Frequency (%) 
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Table 6. 3: Neonatal Morbidities 
Indomethacin Placebo 
p-Value 
N=13 N=13 
    
Severe IVH 3 (23.1%) 3 (23.1%) NS 
Patent Ductus Arteriosus 3 (23.1%) 5 (38.5%) NS 
Necrotizing Enterocolitis 0 (0%) 0 (0%) NS 
Late Onset Sepsis 3 (23.1%) 2 (15.4%) NS 
Mortality 1 (8%) 0 (0%) NS 
Frequency (%) 
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Figure 6. 1: Potential benefit of indomethacin in reducing intermittent 
hypoxemia (IH) in preterm infants. 
Benefit of indomethacin (black) vs placebo (gray) on IH as reflected by percent 
time spent with SpO2<80% (%time-SpO2<80). N=26, p=NS.  
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Figure 6. 2: Potential benefit of indomethacin in reducing intermittent 
hypoxemia (IH) in preterm infants with maternal chorioamnionitis (MC).  
Benefit of indomethacin (black) vs placebo (gray) on IH as reflected by loss of 4-
5 weeks peak in percent time spent with SpO2<80% (%time-SpO2<80). N=6, 
p=NS.  
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Figure 6. 3: Proposed relationship between inflammation and intermittent 
hypoxemia (IH) and potential benefit of indomethacin. 
The relationship between IH and inflammation is bidirectional with inflammation 
worsening IH and subsequently IH increases inflammation leading to further 
respiratory depression. Prenatal inflammation (maternal chorioamnionitis) 
exacerbates the cycle leading to more IH. We speculate that Indomethacin, an 
anti-inflammatory agent; improves IH by ameliorating the described vicious cycle. 
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
 
 Over the past 4 years we have made multiple major contributions to the 
field; especially as it relates to Pediatrics and Neonatal Perinatal Medicine. We 
investigated a clinically significant medical problem (IH) that although has 
profound consequences has not been well studied in preterm infants.  
First, we developed novel methods and processes to perform high fidelity 
studies and accurately assess cardiorespiratory events/IH. We have the ability to 
efficiently collect, post process and analyze bedside monitoring data. We utilized 
high resolution pulse oximeters with 2 second averaging time and 1Hz sampling 
rate. Our analyses IH Automated Analyses Algorithms (IH-AAA) have the 
capacity to import multiple streams of raw data and export detailed IH profiles 
from each subject. Furthermore, the IH profile is an innovative and unique 
method to address this understudied problem. Calculating an IH profile provides 
an enhanced representation of the continuum of the IH problem. Having a good 
representation of the spectrum of the problem may help identify thresholds 
(frequency, duration, severity) beyond which IH leads to neonatal morbidities and 
impairments. These novel measures can be further developed to become part of 
the routine monitoring strategies in the NICU for instantaneous feedback to 
clinical care.  
Second, we reconfirmed finding related to the dynamic natural progression 
of IH in preterm infants.  Di Fiore et al. and Abu Jawdeh et al. first reported from 
a single center study that there is a low frequency of IH in extremely preterm 
infants (less than 28 weeks GA) during the first week after birth, followed by a 
progressive increase by weeks 2-3, with a peak around 4-5 weeks then 
plateau/decrease during weeks 6-8 (1, 2). No other studies have addressed this 
issue or replicated these findings in order to better understand mechanisms in 
the future. We now reproduce this finding from a second center, utilizing an 
expanded patient population of less than 30 weeks GA (versus 28 weeks shown 
before) showing similar IH dynamic frequency until 10 weeks postnatal life 
(versus 8 weeks shown before). The reasons leading to the rise in IH postnatally 
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are poorly defined but likely because of both developing lung disease and 
chemoreceptor dysregulation possibly resulting from inflammation and hypoxia 
(7). Now that these findings have been reproduced, studies should focus on 
understanding further mechanisms and causes for the rise in IH during early 
postnatal life.   
Third, our findings demonstrate the importance of prenatal exposures and 
their effects on postnatal outcomes. We had the unique opportunity to assess the 
relationship between isolated opioid exposure and respiratory instability in 
preterm infants. It was challenging in the past to assess the relationship between 
isolated prenatal opioid exposure and respiratory outcomes/IH, as the majority of 
women who use opioids also smoke or misuse poly-drugs. Our results suggest 
that prenatal opioid exposure is associated with increased IH measures 
compared to unexposed preterm infants. Interestingly, the increased IH 
measures in opioid exposed infants persisted beyond the early postnatal period. 
Another important finding is that the prevalence of opioid exposure in our local 
preterm population is higher than previously reported nationally, thus creating 
urgency toward addressing this significant problem in this vulnerable patient 
population 
 Fourth, we translated and complemented the knowledge we have from 
preclinical animal and bench studies to the clinical setting in preterm infants. We 
showed for the first time in preterm infants that cumulative IH is associated with 
increased markers of inflammation, namely C-reactive Protein (CRP). Our results 
suggest that IH at any of the selected thresholds is associated with increased 
CRP. In addition, we demonstrated that the longer IH events are associated with 
higher CRP levels. These are important findings that shed light on possible 
mechanisms by which IH causes neonatal morbidities and impairment. Future 
longitudinal studies that focus on repeated measures of short and long acting 
markers of inflammation throughout the inflammatory cascade will help define 
mechanisms and better understand this relationship between IH and 
inflammation. 
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Furthermore, our findings support our hypotheses of a bidirectional 
relationship between inflammation and IH. It is well established that systemic 
inflammation leads to increased apnea and subsequently IH (29, 30). In this 
document, we demonstrated that IH may be pro-inflammatory itself. The pro-
inflammatory effects of IH may lead to a vicious cycle (positive feedback loop). 
Apnea events cause IH (oxygen desaturations) and subsequent postnatal 
inflammation systemically and hence in the respiratory control network, 
peripheral chemoreceptors and lungs. The postnatal inflammation leads to a 
further cycle of increased apnea events and consequently higher frequency of IH. 
Interestingly, this phenomenon may be in part responsible for the IH peak at 4-5 
weeks of age. 
Fifth, we demonstrated that maternal chorioamnionitis may be associated 
with increased IH during early postnatal life. No other groups have studied this 
relationship in the past in preterm infants. We speculate that maternal 
chorioamnionitis starts or exacerbates the aforementioned cycle early leading to 
the snowball/spiral effect. Our inconsistent results in this chapter may be related 
to the pathologic definition of MC versus clinical chorioamnionitis. Prospective 
studies investigating the impact of chorioamnionitis (clinical and pathologic) on IH 
may provide mechanistic insights in this understudied relationship between 
inflammation and IH in preterm infants.  
Sixth, our preliminary assessment suggests that indomethacin, a 
commonly used medication in the NICU, may be used in a novel indication; to 
decrease IH in patients born with increased inflammation due to MC. This is the 
first study to test the effect of indomethacin in management of IH in preterm 
infants. This innovative pilot study possibly identified a subset of preterm infants 
(with prenatal inflammation/MC) who may benefit the most from indomethacin to 
reduce IH; an important discovery in the era of precision medicine. A large 
randomized clinical trial is needed to test the efficacy of this promising 
intervention, in management of IH in preterm infants born with perinatal 
inflammation.  
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Seventh, we present in Appendix A a recent publication showing that red 
blood cell transfusion (RBC) decrease IH events beyond the first week of life. We 
also demonstrated a lack of benefit/possible worsening in oxygenation after RBC 
transfusion in the first week of life; an interesting finding now reported twice from 
two separate cohorts. This finding requires further investigation especially after 
possible worsening in oxygenation reported in this study. We also documented 
factors, other than hematocrit, that should be considered before RBC transfusion 
administration; including mechanical ventilation, FiO2 requirement and IH 
measures. Our publication is a stepping stone towards larger studies aimed at 
finding objective bedside measures to guide RBC transfusion administration.     
Eighth, we present in Appendix B a publication addressing the relationship 
between perfusion index (PI) and patent ductus arteriosus (PDA) in preterm 
infants. Perfusion index (PI) is a noninvasive measure of perfusion collected from 
the bedside utilizing our developed methods. Delta PI (ΔPI) is the difference 
between PI measured pre-ductal versus post-ductal. We were able to 
demonstrate that a lower mean ΔPI and pre PI values over a 4-hour period have 
the potential to detect the presence of PDA in premature infants. We were the 
first to report a lower variability in ∆PI in infants with PDA compared to those 
without. This non-invasive measure (PI) is a promising bedside tool to assess for 
PDA in preterm infants. Future studies are needed to determine the clinical utility 
of PI in predicting hemodynamic significance and hence need for PDA treatment 
in preterm infants.  
We have multiple ongoing studies addressing IH from various 
perspectives. A) We are assessing other factors that may influence IH in preterm 
infant. For examples, we hypothesized that delayed cord clamping may reduce 
IH through a rise in both hematocrit and progenitor cells. A bolus of blood and 
progenitor cells from delayed clamping of the umbilical cord may have a lasting 
impact on IH. This study is funded by the Gerber Foundation and we are near 
completion of patient enrollment. B) We are assessing the utility of IH as a 
clinical marker for patient management in the NICU. For examples, among other 
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markers, we are testing IH as a predictor for 1) readiness to discontinue 
mechanical ventilation (extubation readiness) and 2) thresholds for RBC 
transfusions in preterm infants. C) We are assessed the relationship between IH 
and neonatal morbidities. For example, we are investigating the relationship 
between IH and growth impairment in preterm infants. In addition, we completed 
enrollment for a study funded by the Children’s Miracle Network assessing the 
relationship between IH and acute kidney injury (IHAKI study) in preterm infants.  
Finally, a valuable experience throughout this process is working with a 
talented and dedicated multidisciplinary team. Our team encompasses multiple 
divisions, departments, colleges and other institutions and universities. We are a 
solid example of the value of team science during this new era of clinical and 
translational research (201). Our respiratory control research program is one of 
handful programs nationwide able to perform such complex high-fidelity studies 
related to cardiorespiratory events in preterm infants. The team has established 
an excellent working relationship and will continue to tackle complex questions 
involving health of infants. 
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ABSTRACT 
Background 
Red blood cell (RBC) transfusion decreases intermittent hypoxemia (IH) 
events beyond the first week of life. This benefit may be related to improved 
perfusion to the respiratory control network. Perfusion index (PI) is a perfusion 
measure provided by the pulse oximeter. We hypothesized that the benefit in IH 
after RBC transfusion is associated with a rise in PI. In addition, we assessed the 
value of PI and clinical measures in predicting the effect of RBC transfusion on 
IH.  
Study Design and Methods 
We prospectively enrolled infants less than 30 weeks gestational age. PI 
and oxygen saturation (SpO2) were monitored with high-resolution pulse 
oximeters 24 hours pre and post RBC transfusion. Data was analyzed at three 
postnatal periods, epoch 1: first week of life (1 to 7 days of life), epoch 2: 2 to 4 
weeks of life (8 to 28 days of life), and epoch 3: 4 to 8 weeks of life.  
Results 
One hundred eighteen transfusions were analyzed. IH measures 
significantly decreased post transfusion in epochs 2 and 3. PI significantly 
increased after transfusion, but it did not correlate with the decrease in IH 
measures. Mechanical ventilation, fraction of inspired oxygen (FiO2), and IH 
measures influenced the effects on oxygenation.  
Conclusions 
RBC transfusion improved IH after the first week of life. The benefit in IH 
did not correlate with PI increase after transfusion. Pre transfusion respiratory 
support and IH measures predicted the effect of transfusion on oxygenation. 
Key Words: red blood cell transfusion, preterm infants, perfusion, hypoxemia 
 
101 
 
INTRODUCTION 
 Intermittent Hypoxemia (IH), defined as episodic drops in oxygen 
saturation, is common in preterm infants.(1-3) The incidence of IH in extremely 
low gestational age infants changes during the first 2 months of life.(1, 2) There 
is low IH frequency during the first week of life, followed by a progressive 
increase over weeks 2-3, plateaus around 4 weeks, and decreases at weeks 6-
8.(1, 2) Intermittent hypoxemia is associated with both short and long term 
morbidities such as retinopathy of prematurity,(2) neurodevelopmental 
impairment, and late death.(1, 3-5) Red blood cell (RBC) transfusion results in IH 
improvement, particularly beyond the first week of life.(1) Perhaps, the main 
rationale for RBC transfusion in preterm infants is improvement in 
oxygenation.(6) There are two proposed mechanisms for beneficial effect of RBC 
transfusion on oxygenation. The first relates to greater cardiovascular stability 
with increased perfusion to the respiratory control network leading to improved 
central respiratory drive and subsequent less IH.(1, 7-9) The second suggests 
greater stability of oxygenation due to a rise in hematocrit leading to less IH in 
the presence of apnea.(1),(10)  
Perfusion index (PI) is a noninvasive measure of perfusion provided by the 
bedside pulse oximeter. Perfusion index is calculated from the ratio of the 
pulsatile to non-pulsatile signal at the monitoring site.(11, 12) Perfusion index 
correlates with superior vena cava flow,(13) detects critical left heart obstructive 
disease,(14) and patent ductus arteriosus.(15, 16) Furthermore, Kanmaz et al. 
noted that RBC transfusion is associated with a significant increase in PI and 
suggested that PI may be a useful marker for the need of transfusion.(17) 
Therefore, we wanted to assess if the benefit in IH seen after RBC transfusion is 
associated with a rise in PI in preterm infants at different postnatal ages. In 
addition, we assessed the predictive value of PI, hematocrit, mechanical 
ventilation, fraction of inspired oxygen (FiO2) and IH; in order to identify infants 
who will benefit the most from the RBC transfusion in terms of oxygenation. 
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MATERIALS AND METHODS 
Study Design and Data Collection 
This was a prospective cohort study conducted at the University of 
Kentucky Medical Center Neonatal Intensive Care Unit between November 2014 
and October 2015. The study was approved by the University of Kentucky 
Institutional Review Board. Infants with gestational age (GA) less than 30 weeks 
were approached in the first week of life and informed consent was obtained from 
parent(s). Infants were then followed and oxygen saturation was continuously 
monitored in the first 2 months of life. Infants who received RBC transfusion per 
the NICU transfusion guidelines were included in the analyses. The following is a 
summary of the local NICU transfusion guidelines: Hematocrit threshold of <35% 
for mechanically ventilated neonates or FiO2 requirement >40%, hematocrit 
<28% for infants on non-invasive respiratory support or FiO2 requirement <40%, 
and hematocrit <22% for neonates on no respiratory support. RBC transfusion at 
15ml/kg was administered over a 3 hour period. Oxygen saturation (SpO2) and PI 
were monitored using continuous high-resolution (2s averaging time and 1Hz 
sampling rate) pulse oximeters (Radical 7: Masimo, Irvine, CA, USA). The target 
oxygen saturation in our unit is 90-95%. Patients were continuously monitored for 
the first 8 weeks of life and data was stored on serial data recorders. Novel 
programs were utilized to filter (Matlab, Natick, MA, USA) and analyze (SAS 
Institute, Cary, NC, USA) data. Variables related to demographics, weight, 
respiratory measures and medications were collected.  
The primary outcome measures for IH were defined as 1) a drop in SpO2 
to less than 80% for ≥4s and ≤3min duration (IH-SpO2<80) and 2) overall percent 
time spent with SpO2 <80% (%time-SpO2<80). The lower limit of 4s duration was 
based on the previous data by Abu Jawdeh et al. and the upper limit of 3 min 
duration was used to differentiate intermittent from sustained hypoxemia.(1) 
Other outcome measures included additional SpO2 thresholds of 85% and 90%.  
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A RBC transfusion was eligible for analysis if no other RBC transfusion 
was administered 24 hours pre or post transfusion. We then analyzed changes in 
IH frequency (IH-SpO2<80, IH-SpO2<85, IH-SpO2<90), percent time spent below 
threshold (%time-SpO2<80, %time-SpO2<85, %time-SpO2<90), mean PI, and 
variability of PI during the 24 hours pre and post RBC transfusion. Additionally, 
we determined the associated changes in hematocrit and respiratory 
characteristics. 
To account for the effect of postnatal age on IH following RBC 
transfusion(2), the 8-week monitoring period was stratified into three epochs and 
analyzed separately; epoch 1: first week of life (1 to 7 days of life), epoch 2: 2 to 
4 weeks of life (8 to 28 days of life), and epoch 3: 4 to 8 weeks of life.(1) In order 
to assess which preterm infants benefit the most from RBC transfusion, we 
evaluated the predictive value of the following pre RBC transfusion variables: PI, 
hematocrit, mechanical ventilation, FiO2 requirement, and IH primary measures. 
 
Statistical Analysis 
To compare epochs in Table 1, continuous variables were presented as 
mean ± standard deviation (SD) and categorical variables were expressed as 
frequencies and percentages.  Sample means and SDs were also utilized in 
Figures 2 and 3 to visually compare pre and post RBC transfusion values for 
each epoch. Pearson’s correlations were used to quantify associations between 
changes in different variables.  To account for statistical correlation arising from 
repeated measurements, i.e. multiple observations per subject, generalized 
estimating equations with robust standard errors were utilized for inference.  
Finally, linear mixed models with robust standard errors were utilized to obtain 
results for Table 3, in which change in IH measures (IH-SpO2<80 or %time-
SpO2<80) after RBC transfusion was the outcome of interest.  The primary 
predictors were pre RBC transfusion mechanical ventilation, FiO2 requirement, 
and pre RBC transfusion IH measures.  The models also controlled for pre RBC 
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transfusion PI and hematocrit.  All tests were two-sided at the 5% significance 
level.  Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, NC, 
USA). 
 
RESULTS 
Fifty preterm infants met criteria for enrollment. Thirty-nine infants 
received RBC transfusions that were eligible for analysis for a total of 118 
transfusions (22, 63 and 33 RBC transfusions in epochs 1, 2, and 3, 
respectively). The median (IQR) of eligible transfusions were as follows: 2(1-2), 
5(3-7) and 8(6-10) for epochs 1, 2, and 3, respectively (Table 1). Figure1 shows 
the flow diagram for patient enrollment, transfusion eligibility, and number of 
infants who received transfusions during each epoch. There were no significant 
differences in GA, birth weight, gender, and race across all 3 epochs (Table 1).  
The majority of infants required respiratory support, supplemental oxygen and 
caffeine therapy (Table 1). The FiO2 requirement (mean ± standard deviation) 
increased to 35.2% ±11.6 (p=0.1), 43.7% ± 19.3 (p=0.9) and 47.8% ± 24.7 
(p=0.3) in epochs 1, 2 and 3 respectively but was not statistically significant.  
 
Changes in Measures Pre and Post RBC Transfusion 
As represented in Figure 2A, there was a statistically significant but 
minimal increase in mean 24 hour PI after RBC transfusion across all epochs. 
There was no difference in variability of PI between pre and post RBC 
transfusion in all 3 epochs (pre-post: -0.07 ± 0.33, p=0.2; -0.01 ± 0.12, p=0.5; -
0.05 ± 0.15, p=0.1 in epochs 1, 2 and 3 respectively). In epoch 1, there was no 
change in IH-SpO2<80 and IH-SpO2<85 post RBC transfusion; interestingly, 
there was a significant increase in IH-SpO2<90 (Figure 3). Overall, %time-
SpO2<80, %time-SpO2<85 and %time-SpO2<90 did not significantly change in 
epoch 1 (Figure 3). In epochs 2 and 3, we found a significant decrease in IH-
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SpO2<80 and IH-SpO2<85 and no change in IH-SpO2<90 (Figure 3). Overall 
%time-SpO2<80% and %time-SpO2<85 improved in epoch 2 and 3 with no 
changes in %time-SpO2<90. As expected, mean hematocrit significantly 
increased 24 hours after RBC transfusion across all three epochs (Figure 2B).  
 
Correlations of Changes Pre and Post RBC Transfusion 
There was no significant correlation between changes in PI and IH pre 
and post RBC transfusion in any of the 3 epochs (Table 2). There was no 
correlation between changes in hematocrit and IH pre and post RBC transfusion 
in epochs 1 and 2 (Table 2). In epoch 3, there was a positive correlation between 
the change in hematocrit and IH measures that was statistically significant for 
%time-SpO2<80 (Table 2).  
 
Factors Associated with the Effect of RBC Transfusion on IH measures 
Linear mixed models were utilized to assess factors that influenced the 
effect of RBC transfusion on IH.  The models controlled for pre RBC transfusion 
PI, hematocrit, mechanical ventilation, FiO2 requirement and IH-SpO2<80 or 
%time-SpO2<80.  The results are presented in Table 3. 
 
DISCUSSION 
Our study shows an increase in perfusion (as represented by the rise in 
PI) after RBC transfusion. However, this increase does not correlate with the 
improvement in oxygenation. Consistent with Abu Jawdeh et al.,(1) our study 
shows that IH improved post RBC transfusion only beyond the first week of 
life.(2) In addition, our results replicate the lack of benefit in oxygenation after 
RBC transfusion in the first week of life. This study also demonstrates that pre 
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RBC transfusion mechanical ventilation need, FiO2 requirement and IH measures 
influence the effect of RBC transfusions on oxygenation.  
Similar to a study by Kanmaz et al.,(17) our results show a significant 
increase in PI post RBC transfusion. The increase in PI is minimal and may not 
be clinically significant. The observed increase in PI did not correlate with a 
decrease in IH measures following RBC transfusion. The effect of RBC 
transfusion on PI may be related to volume expansion. In contrast, RBC 
transfusion effect on IH is likely due to changes in oxygen carrying capacity and 
stabilization of oxygenation.(6, 10, 18) 
The effect of RBC transfusion on IH varied based on postnatal age. There 
was significant improvement in oxygenation after RBC transfusion in epochs 2 
and 3. However, there was no significant change in IH measures after RBC 
transfusion during the first week of life; in fact, an increase in IH frequency 
occurred for IH-SpO2<90. This increase in IH events in epoch 1 after transfusion 
for IH-SpO2<90 reflects the increase in milder events (SpO2 ≥85%); although all 
trended in the same direction. The etiology of this reproducible lack of benefit in 
oxygenation after RBC transfusion in early postnatal life is unknown, but may be 
influenced by multiple factors. The lack of benefit may be related to the already 
low incidence of IH during this period.(1, 2) Other factors may include inadequate 
compensatory mechanisms to overcome the changes in blood flow, volume 
status and blood viscosity associated with RBC transfusion during early postnatal 
life.(6, 18-20) Furthermore, the higher proportions of high-affinity fetal 
hemoglobin in early postnatal life may have an impact on the effect of RBC 
transfusion on oxygenation.(10),(20)  The lack of benefit in oxygenation after RBC 
transfusion in the first week of life raises important concerns regarding liberal 
transfusion thresholds during early postnatal life and the need to further evaluate 
any adverse respiratory effects in this time period. In addition, studies to further 
evaluate mechanisms and factors that influence the effect of RBC transfusion on 
IH in the first week of life are imperative.  
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Respiratory support (mechanical ventilation and FiO2) and IH measures 
influenced the effect of RBC transfusions on oxygenation (Table 3). As expected, 
patients on mechanical ventilation benefited more from RBC transfusion 
compared to extubated infants in epoch 2 and approached significance in epoch 
3. Interestingly, in epoch 1, patients on mechanical ventilation had no 
improvement or worsening in oxygenation after RBC transfusion. We speculate 
the findings seen in the first week of life in ventilated infants may relate to patient 
characteristics including immaturity of compensatory mechanisms, severe lung 
disease with poor pulmonary reserves and subsequent lung fluid overload from 
RBC transfusion.(6, 10, 20) Increased FiO2 requirement pre RBC transfusion was 
associated with a significant decrease in IH measures post transfusion during 
epoch 1. After the first week of life, higher IH measures pre RBC transfusion 
were associated with greater benefit in oxygenation that was statistically 
significant in epoch 2 and approached significance (p=0.053) in epoch 3. Extent 
of FiO2 requirement and IH measures are closely related as FiO2 adjustment is 
often based on oxygen desaturations. Our sample size may not have been large 
enough to reach statistical significance in all epochs; however, FiO2 and IH 
measures are promising objective tools able to guide transfusion management. 
Overall, the results of the study show that postnatal age, along with type of 
respiratory support and IH measures, influence the effect of RBC transfusion on 
oxygenation. Further studies to evaluate mechanisms as to how these factors 
influence the effect of RBC transfusion on IH are needed. 
Maintaining hematocrit above a certain consensus threshold is the major 
indication for RBC transfusion in NICUs worldwide.(21, 22) Consistent with 
previous studies, our results suggest that hematocrit alone is a weak predictor of 
the effect of RBC transfusion on oxygenation.(1, 5, 7, 9, 23, 24) Although 
hematocrit significantly increased post RBC transfusion, the change in hematocrit 
did not correlate with improved oxygenation after RBC transfusion except in 
epoch 3 where a poor correlation was noted (Table 2). We speculate that 
hematocrits are closely followed in the NICU and the levels in our infants may not 
have been low enough to result in significant cardiorespiratory instability. 
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A limitation to this study is not having evaluated other hemodynamic 
factors such as blood pressure, heart rate, and volume status. We also lack 
documentation of other neonatal morbidities that may have affected PI and 
oxygenation such as presence of intraventricular hemorrhage, patent ductus 
arteriosus, and sepsis. As our model included multiple variables, the current 
sample size may have lacked sufficient power to reach significance in certain 
epochs. The possible variation in RBC transfusion indications among providers is 
a limitation, but likely minimized by our unit consensus transfusion guidelines.   
 
CONCLUSION 
Red blood cell transfusion is associated with decreased IH events after 
the first week of life. The lack of benefit in oxygenation after RBC transfusion in 
the first week of life is an interesting finding now reported twice from two 
separate cohorts. This finding requires further investigation especially after 
possible worsening in oxygenation reported in this study.  Our primary aim to 
assess the value of PI as an indication for RBC transfusion did not yield positive 
findings. We documented factors, other than hematocrit, that should be 
considered before RBC transfusion administration; including mechanical 
ventilation, FiO2 requirement and IH measures. Our study is a stepping stone 
towards larger studies aimed at finding objective bedside measures to guide 
RBC transfusion administration.     
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TABLE 1 Baseline characteristics of enrolled patients among epochs 
  
Epoch 1 Epoch 2 Epoch 3 
p value 
n=22 n=63 n=33 
   Gestational age in weeks (n)            
(Mean ± SD) (22) 25.8 ± 1.3 (62) 25.6 ± 1.3 (33) 25.6 ± 1.2 0.8 
   Birth weight in grams (n) (Mean ± SD) (22) 807 ± 162 (62) 796 ± 171 (33) 803 ± 179 0.94 
   Postnatal age in days (n)           
(Mean ± SD) (22) 4.6 ± 1.6 (62) 18.0 ± 6.4 (33) 43.5 ± 8.9 <0.001 
Weight day of transfusion in grams 
(n) (Mean ± SD) (22) 808 ± 153 (62) 982 ± 247 (33) 1475 ± 434 <0.001 
   Number of Transfusions per patient, 
Median (IQR) (22) 2 (1-2) (63) 5 (3-7) (33) 8 (6-10) <0.001 
   Male, n (%) 15/22 (68%) 36/62 (58%) 21/33 (64%) 0.7 
   Caucasian, n (%) 17/22 (77%) 53/61 (87%) 27/33 (82%) 0.7 
   Respiratory Support 
    
     Conventional ventilator, n (%) 18 (86%) 50 (86%) 21 (68%) 0.22 
     Non-invasive ventilation, n (%) 3 (14%) 8 (14%) 10 (32%) 
 
     NIPPV, n (%) 2 (10%) 6 (10%) 7 (23%) 
 
     CPAP, n (%) 1 (5%) 2 (3%) 3 (10%) 
 
Missing data for type of respiratory 
support, n (%) 1 (5%) 5 (8%) 2 (6%)  
   Supplemental oxygen, n (%) 19/21 (90%) 54/58 (93%) 29/31 (94%) 0.92 
   Pre RBC transfusion FiO2 (n)          
(Mean ± SD) (21) 30.0 ± 9.3 (59) 42.7 ± 21.0 (31) 44.8 ± 20.8 <0.001 
   Caffeine, n (%) 21/22 (95%) 62/62 (100%) 31/33 (94%) 0.55 
aSD, standard deviation; bNIPPV, nasal intermittent positive pressure ventilation; cCPAP, continuous 
positive airway  pressure; p for mean difference; 
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TABLE 2 Correlations of changes in PI, Hematocrit and IH 
  Epoch 
ΔIH Events < 80%  Δ%time < 80%   
 r p value  r p value 
Δ Perfusion Index  
1 -0.05 0.46 -0.18 0.61 
2 0.18 0.13 0.14 0.38 
3 -0.16 0.22 0.07 0.51 
Δ Hematocrit  
1 0.1 0.33 -0.03 0.88 
2 -0.11 0.37 -0.05 0.86 
3 0.271 0.08 0.322 0.02 
 aΔ represents change in value: post RBC transfusion - pre RBC transfusion. br = 
correlation coefficient 
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FIGURE 1: Flow diagram for patient enrollment and transfusion eligibility  
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FIGURE 2: Mean PI and Hematocrit levels for all the 3 epochs pre and post RBC 
transfusion. There was a statistically significant increase in the PI (A) and 
hematocrit (B) after RBC transfusion in all the three epochs (*p<0.05). 
Mean/standard deviation 
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FIGURE 3: IH events/day and % time below threshold pre and post transfusion. 
3A-C: IH-SpO2<80 and IH-SpO2<85 decreased in epochs 2 and 3 (*p<0.04) while 
IH-SpO2<90 increased in epoch 1 (*p=0.04). 3D-F: % time-SpO2<80 and % time-
SpO2<85 decreased in epochs 2 and 3 (*p<0.04). There was a decrease in % 
time-SpO2<90 in epochs 2 (p=0.2) and 3 (p=0.3) and increase in epoch 1 
(p=0.07). Mean/standard deviation 
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ABSTRACT 
Background  
Perfusion index (PI) is a noninvasive measure of perfusion. ΔPI 
(difference between pre- and postductal PI) may identify hemodynamically 
significant PDA. However, studies are limited to brief and intermittent ΔPI 
sampling. Our objective is to assess the value of continuous high resolution ΔPI 
monitoring in the diagnosis of PDA. 
Methods 
Continuous ΔPI monitoring in preterm infants was prospectively performed 
using two high-resolution pulse oximeters. Perfusion Index measures (ΔPI mean 
and variability, pre- and postductal PI) were analyzed over a 4-h period prior to 
echocardiography. A cardiologist blinded to the results evalu- ated for PDA on 
echocardiography. Linear mixed regression models were utilized for analyses. 
Results  
We obtained 31 echocardiography observations. Mean ΔPI (−0.23 vs. 
0.16; P < 0.05), mean pre-PI (0.86 vs. 1.26; P< 0.05), and ΔPI variability (0.39 
vs. 0.61; P = 0.05) were lower in infants with PDA compared to infants without 
PDA at the time of echocardiography. 
Conclusion 
Mean ΔPI, ΔPI variability, and mean pre-PI measured 4 h prior to 
echocardiography detect PDA in pre- term infants. PI is dynamic and should be 
assessed continu- ously. Perfusion index is a promising bedside measurement to 
identify PDA in preterm infants. 
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BACKGROUND 
Patent ductus arteriosus (PDA), a common condition in pre- term infants, 
leads to shunting of blood between the systemic and the pulmonary circulations. 
Approximately 65% of infants born between 25 and 28 wk gestational age (GA), 
and 85% of those born at 24 wk GA will have PDA at first week of life (1). 
Persistent patency is associated with adverse outcomes, including prolonged 
assisted ventilation and higher rates of death, bronchopulmonary dysplasia, 
pulmonary hemorrhage, necrotizing enterocolitis, impaired renal function, 
intraventricular hemorrhage, periventricular leukomalacia, and cere- bral palsy 
(1,2). Because of these associated complications, majority of infants < 28 wk GA 
will receive medical or surgical therapy in an attempt to close the PDA (1–3). 
Currently, the gold standard for PDA diagnosis is echocardiography (2, 4–8), and 
often clinical symptoms are not associated with echocar- diography findings 
(1,4). 
Perfusion index (PI) is a noninvasive measure for monitoring the general 
hemodynamic status of the preterm infant (9–11). Perfusion index provides 
assessment for the pulse strength and is derived from pulse oximetry. PI, 
measured by infrared light, is calculated as the ratio of the pulsatile (AC) to 
nonpulsatile components (DC) of the blood flow in tissue (9,10,12,13). In 
neonates, PI has clinical application. Granelli et al. (14) corre- lated lower PI 
values in infants with critical left heart obstructive disease. In addition, De Felice 
et al. (15) reported that PI was decreased in infants born to mothers with 
chorioamnionitis. 
Reports are inconsistent as to the value of PI in the assess- ment of PDA. 
This may be attributed in part to location and the duration of PI measurements 
(12,16). Khositseth et al.(16) hypothesized that the peripheral perfusion of the 
lower extremities (postductal) is decreased compared to the right arm (preductal) 
in preterm infants with hemodynamically significant patent ductus arteriosus 
(hsPDA). This difference is due to left-to-right shunt across the ductus arteriosus 
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into the pulmonary artery. They reported that a difference in PI between the 
upper and the lower extremity, or delta PI (∆PI), of more than 1.05% strongly 
correlated with the echocardio- graphic diagnosis of hsPDA (sensitivity: 66.7%, 
specificity: 100%, positive predictive value: 100% and negative predictive value: 
86.4%). Their study was limited by a one-time obser- vation that may not be 
reflective of the hemodynamic vari- ability of perfusion in infants with PDA. 
Alternatively, Vidal et al. (12) conducted a study to evaluate the postductal PI of 
premature infants in order to categorize the PDA status and found that postductal 
PI did not correlate with PDA and was not influenced by ductal flow pattern. 
We conducted a prospective study to assess the value of ∆PI in the 
diagnosis of PDA in preterm infants, using high resolu- tion continuous pre- and 
postductal monitoring. 
 
METHODS 
This prospective study was conducted at a level IV NICU between 
November 2014 and July 2015. The study was approved by the Institutional 
Review Board of the University of Kentucky and parental informed consent was 
obtained in all cases. Infants with GA ≤ 29 wk were enrolled on the first day of life 
and followed for a 2-wk period. Infants with major congenital malformations were 
excluded. Those infants in which we had an echocardiography and adequate PI 
data for 4 h prior to the echocardiography were chosen for analysis. 
 
Perfusion Index Measurement 
Perfusion index was continuously monitored using high resolution (2 s 
averaging time, 1 Hz sampling rate) pulse oximeters (Masimo Radical Masimo 
Corporation, Irvine, CA). In order to capture echocardiograms performed for PDA 
assessment, data were recorded continuously during the first 14 d of life. 
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Subjects were connected to two pulse oximeters simultaneously; right upper 
extremity for pre-ductal monitoring and either lower extremity for postductal 
monitoring. Data from pulse oximeters were continuously stored to serial data 
recorders. The pre- and postductal PI difference (ΔPI) was defined as the PI 
measured preductal minus the PI measured postductal (16). 
 
Echocardiography 
Two-dimensional, color Doppler, spectral Doppler, and M-mode 
echocardiography was performed to assess for PDA at the discre- tion of the 
attending physician using a Phillips IE33 echocardiog- raphy machine with 12-
MHz transducer. A cardiologist, blinded to the results of the study, independently 
examined the echo images and categorized subjects into the following three 
groups: (i) hemodynami- cally significant PDA (hsPDA); (ii) nonhemodynamically 
signifi- cant PDA (non-hsPDA), and (iii) no PDA. The definition of hsPDA 
included infants with at least two of the following: (i) ductal diameter at the 
pulmonary side ≥ 1.4 mm/kg; (ii) left atrial to aortic ratio ≥ 1.5;(iii) left pulmonary 
artery (LPA) mean flow velocity of ≥ 0.42 m/s; and (iv) LPA end-diastolic velocity 
of ≥ 0.2 m/s (3,5,7,17–19). 
 
Sample Size 
In order to determine the minimum sample size needed to assess the 
value of ∆PI in PDA diagnosis, we utilized the results reported in the pilot data by 
Khositseth et al. (16). Assuming the ∆PI (%) mean and SD are 1.00 and 0.70, 
respectively, for children with PDA and 0.04 and 0.10, respectively, for children 
with no PDA, we calculated a total required study sample size of 15 infants 
(power 80%, p<0.05). 
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Data Management and Statistical Analysis 
The pulse oximeters serial data recorders were time synced. Perfusion 
Index sampling rate was 1Hz (every second). However, there were rare 
occurrences of two values per second. In such cases, the average value for the 
given second was utilized. In order to better visualize an example of PI values 
over time (Figure 2), we plot PI values that were averaged over each minute. 
Any given value, at any given second, by itself will not represent a true overall 
reflection of PI for the duration of several hours, and thus cannot be used to 
accurately predict PDA. We therefore decided, for predictive purposes, to assess 
the utility of average ΔPI values during the 4 h prior to an echocardiography as a 
single measure of PI to predict PDA which could better represent the 
hemodynamic status of preterm infants. This period of 4 h will capture changes 
resulting from the ultradian rhythm that has been reported in premature infants 
(20). Subjects with 4 h of adequate monitoring prior to the echocardiography 
were considered for analysis. Artifacts and extreme values, found in less than 2% 
of PI measurements, were removed as they were associated with inadequate 
signal capture. 
Data analyses were conducted by a statistician. The primary outcome of 
interest is the average ∆PI during the 4 h leading up to echo- cardiography and 
pre- and postductal PI were secondary outcomes. Furthermore, PI variability was 
analyzed by using the outcome of the SD of the individual PI values over the 4 h. 
When comparing mean  values for no PDA, non-hsPDA and hsPDA, linear mixed 
regression models were utilized in order to account for repeated measurements 
in subjects with multiple echocardiograms. The Kenward and Roger degrees of 
freedom method was used for inference (21). Generalized estimating equations 
with the Kauermann and Carroll correction (22) and between-within degrees of 
freedom were used to evaluate base- line differences among groups defined by 
PDA status. Analyses were conducted in SAS Version 9.4 (SAS Institute, Cary, 
NC). All tests were two-sided at the 5% significance level. 
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RESULTS 
A total of 40 infants were enrolled upon admission. Of these, 4 had no 
echocardiography performed and 16 had missing PI data or artifacts during the 
study period. Final analyses included data from 20 infants with a total of 31 
echocardiography observations (each infant was observed at 1 to 3 occasions) 
(Figure 1). Eighteen infants were found to have PDA on echocardiography. The 
characteristics at birth of the infants did not significantly differ between those with 
and without PDA, as shown in Table 1. The baseline characteristics of the infants 
at the time of echocardiography are presented in Table 2; no statistically 
significant differences were noted among groups. As represented in Figure 2, PI 
values were found to be highly variable with changes every minute. 
 Mean ΔPI differed signifi antly between infants with PDA and without PDA 
(Figure 3). Mean pre- and postductal PI values are presented in Figure 4. The 
preductal PI was significantly elevated in infants without PDA as compared to 
infants with PDA. Among the PDA subgroups, the preductal PI of those with non- 
hsPDA was lower compared to infants without PDA (Figure 4). The mean 
postductal PI did not differ among groups (Figure 4). 
Variability of ΔPI, pre- and postductal PI is presented in Figure 5. ΔPI 
variability was significantly lower in infants with PDA compared to no PDA. 
Although not statistically significant, the PI variability is consistently low in infants 
with PDA for pre- and postductal measures. 
 
DISCUSSION 
Our study demonstrates that the mean ΔPI, mean pre-PI and the ∆PI 
variability can identify PDA in premature infants. Mean values of ∆PI, pre- and 
postductal PI and ∆PI variability were continuously calculated over the 4-h period 
prior to echocardiography compared to intermittent measures as previously 
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described (11,12,14,23,24). Our observations are somewhat contradictory to 
initial expectations related to changes in pre-ductal PI and ΔPI. We expected to 
observe a steady preduc- tal PI and a decreased postductal PI leading to a larger 
ΔPI in infants with PDA. The negative ΔPI (Figure 3) is likely a combination of a 
decreased preductal PI (reported by Karadag et al. (25)) and a postductal PI that 
is either steady (reported by Vidal et al. (12)) or increased (reported by 
Alderliesten et al.(9)). These results have a combined effect towards a negative 
ΔPI value found in infants with PDA. 
We found the preductal PI to be significantly lower in infants with PDA 
compared to infants without PDA (Figure 4). To understand this result, we refer 
to the definition of PI (AC/DC*100) (15,26), wherein AC is the pulsatile 
component of the signal and DC is the  nonpulsatile  component.  Infants with 
PDA can have an absent or reverse flow during diastole in the postductal sites 
but continuous forward blood flow in the preductal sites (7,8). In infants with PDA, 
there is also an increase in the cardiac output to compensate for the decreased 
perfusion in the postductal sites (27–29). This change in cardiac output increases 
the preductal DC component in infants with PDA compared to no PDA; 
explaining why the preduc- tal PI is lower in these infants. Our results are 
consistent with Karadag et al. (25) who analyzed the preductal PI in infants 
treated with surfactant. They found that the incidence of PDA was greater among 
the infants with a lower preductal PI. 
Our study shows no difference between mean postductal PI in infants with 
PDA and no PDA. Our findings are consistent with Vidal et al. (12) who found no 
statistically significant difference or correlation between postductal PI and PDA in 
premature infants. Although not statistically significant, the postductal PI was 
higher in our infants with PDA compared to infants without PDA (Figure 4). We 
believe that with PDA there is a decrease in the DC component of the postductal 
PI due to the overall lower perfusion and decreased mean arterial pressure at the 
postductal sites (30,31). Furthermore, our find- ings are consistent with the report 
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by Alderliesten et al. (9) who found in a study of 342 neonates that infants with 
hsPDA had higher postductal PI than infants without hsPDA. They attrib- uted 
this finding to a hyperdynamic circulation with a widened pulse-pressure resulting 
in an increase in the AC component. We believe that the increase in postductal 
PI, if present, is the result of a combination of the effect of the elevated AC 
component (due to the hyper-dynamic circulation) and a decreased DC 
component (due to a decreased general perfusion). 
Given that the mean ∆PI may not reflect instantaneous hemodynamic 
changes, we also assessed the variability of the ∆PI over the 4-h monitoring 
period. Since the correlation of blood fl w and PI has already been established 
(11, 32), we believe that the ∆PI variability should also correlate with the 
hemodynamic status of the infant. Our fi dings show that infants with PDA have 
signifi antly lower ∆PI variability compared to those with no PDA (Figure 5). 
Although trending in the same direction, changes in variability were not 
statistically significant for pre- and postductal PI (Figure 5). The change in ∆PI 
variability observed in our study is noteworthy since it has not been previ- ously 
described. De Felice et al. (15) speculated that changes in PI variability may be 
associated with neonatal morbidities, similar to heart rate variability. Decreased 
heart rate variability in preterm infants with PDA was described by Prietsch et al. 
(33). This decreased heart rate variability resolved after treatment with 
indomethacin. ΔPI and heart rate variability are valuable at identifying subclinical 
cardiovascular dysfunction in pre- term infants (15). The variable PI, as a refl 
ction of the changing hemodynamic status of infants, may also explain the 
discrepancy among PI values reported in different studies (9,13,14,23,24). 
Compared to other studies (11,12,14,23,24), we measured PI with high 
resolution (1s sampling rate) continuous pulse oximetry which gives our study the 
strength of having high quality monitoring for long periods of time. We advocate 
for continu- ous measurement of PI compared to spot checks; however, the 
question that remains to be answered is the optimal monitoring duration needed 
to detect hemodynamic instability. 
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The echocardiographic classification of hsPDA used in this study is 
commonly reported in the literature (8,30,31) but did not correspond to the 
clinical status of our infants. Those infants designated by echocardiography as 
hsPDA required less mechanical ventilation, had less FiO2 requirement, and no 
difference in acidosis compared to non-hsPDA; although not statistically 
significant (Table 2). It is possible that mechanical ventilation may have an effect 
on PI measures; however, our sample size does not allow to determine an 
independent effect of ventilation on PI changes. Our study was not designed to 
establish any correlation between the PI values and the clini- cal severity of the 
ductus arteriosus. Even though the ductal stealing phenomenon in infants with 
PDA is well known (17,30,31), its relationship with end organ hypoperfusion and 
neonatal morbidity remains controversial (34). 
Although we achieved the planned observations per our power calculation 
(accounting for data loss), our sample size is small to evaluate other factors that 
may affect PI values. Our study has the strength of offering continuous high-
quality monitoring throughout the study period. This allowed us to adequately 
assess the relationship between PI and PDA. 
We were able to demonstrate that a lower mean ΔPI and pre PI values 
over a 4-h period have the potential to detect the presence of PDA in premature 
infants. We are the first to report a lower variability in ∆PI in infants with PDA 
compared to infants without PDA. Perfusion index provided by the bedside 
monitor is a promising bedside tool to assess for PDA in preterm infants. Future 
studies with a large cohort are needed to determine the clinical utility of PI in 
predicting PDA and monitoring of its hemodynamic course through days of 
treatment. 
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Figure 1.  Flow diagram of the enrolled patients. 
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Figure  2.  Sample plot representing PI values of one infant with PDA (Variability 
0.33, Mean −0.01) and no PDA (Variability 0.71, Mean 0.87) for 4 h prior to an 
echocardiogram. Dashed lines represent the preductal PI and solid lines 
represent the postductal PI. 
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Figure 3. Mean ± SD values of Delta Perfusion Index (ÄPI) 4 h prior to 
echocardiography. Comparing ÄPI in infants with no PDA vs. infants with PDA, 
hemodynamically significant PDA (hsPDA) and no hsPDA. *P < 0.05 compared 
to no PDA. 
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Figure 4. Mean ± SD values of Perfusion Index (PI) 4 h prior to echocar- 
diography. Comparing the preductal (black bar) and postductal (white bar) PI of 
infants with no PDA vs. infants with PDA, hemodynamically significant PDA 
(hsPDA) and no hsPDA. *P < 0.05 compared to no PDA. 
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Figure 5. Mean ± SD values of the Variability of Perfusion Index (PI) 4 h prior to 
echocardiography. Comparing ∆PI (dotted bar), preductal PI (black bar) and 
postductal PI (white bar) variability for infants with no PDA vs. with PDA, 
hemodynamically significant PDA (hsPDA) and no hsPDA. *P < 0.05 and ‡P = 
0.08 compared to no PDA. 
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Bada HS, Giannone PJ, Desai N, Abu Jawdeh EG. 
Relationship between Postnatal Weight Gain and Intermittent 
Hypoxemia (IH) in Preterm Infants. Annual CCTS Spring 
Conference. UK Center for Clinical and Translational Science. 
Lexington Kentucky.  Poster session. 
34. 05/2017 Patra A, Bhandary P, Hanna M, Abu Jawdeh EG, 
Gomez Pomar E, Barber G, Subedi L, Carpenter A, Haynes S, 
Giannone P. Reducing Incidence Of Severe Intraventricular 
Hemorrhage In Extremely Premature Infants: A Quality 
Improvement Initiative. Pediatric Academic Societies (PAS), 
San Francisco, California.  Poster session 
35. 05/2017 Bhandary P, Savardekar H, Abu Jawdeh EG, 
Giannone PJ, Hanna M, Patra A, Differences in Sodium 
Measurements between Point of Care and Laboratory Analyzers 
in ELBW Infants During the First Week of Life. Pediatric 
Academic Societies (PAS), San Francisco, California.  Poster 
session. 
36. 05/2017 Raffay TM, Dylag A, Abu Jawdeh EG, Martin RJ, 
Di Fiore JM. Neonatal Intermittent Hypoxemia May Predict 
Bronchopulmonary Dysplasia Risk. Pediatric Academic 
Societies (PAS), San Francisco, California.  Poster session. 
37. 05/2017 Bhandary P, Patra A, Hanna M, Abu Jawdeh EG, 
McGee L, Haynes S, Giannone P. Decreasing Phlebotomy in 
Preterm Infants by Successful Utilization of Cord Blood for 
Admission Testing. Pediatric Academic Societies (PAS), San 
Francisco, California.  Poster session. 
38. 05/2017 Pant A, Westgate P, Raffay T, Gabrani A, Brasher 
M, Bada HS, Giannone P, Cunningham MD, Abu Jawdeh EG. 
Extubation Failure in Preterm Infants: A Role for Monitoring 
Intermittent Hypoxemia. Pediatric Academic Societies (PAS), 
San Francisco, California. Poster session. 
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39. 2/2018  Abu Jawdeh EG, Westgate P, Pant A, Stacy  A,  
Patwardhan  A,  Bada  H, Giannone  P. Relationship between 
Intermittent Hypoxemia and Inflammation in Preterm Infants: 
Vicious Cycle. Southern Society for Pediatric Research. New 
Orleans February.  Poster session. 
40. 4/2018 Strelow F, Westgate P, Pant A, Patwardhan A, 
Bada H, Giannone P, Desai N, Abu Jawdeh EG Evaluation of 
Postnatal Growth and Caloric Intake in Relation to Intermittent 
Hypoxemia. Annual CCTS Spring Conference. UK Center for 
Clinical and Translational Science. Lexington Kentucky.  
Podium Presentation (Strelow).   
41. 4/2018 Stacy A, Westgate P, Patwardhan A, Bada H, 
Giannone P, Abu Jawdeh EG. Pathologic Maternal 
Chorioamnionitis and Intermittent Hypoxemia in Preterm Infants. 
Annual CCTS Spring Conference. UK Center for Clinical and 
Translational Science. Lexington Kentucky. Poster Session 
42. 5/2018  Strelow F, Westgate P, Pant A, Patwardhan A, 
Bada H, Giannone P, Desai N, Abu Jawdeh EG. Relationship 
between Postnatal Growth, Caloric Intake and Intermittent 
Hypoxemia (IH) in Preterm Infants. Pediatric Academic 
Societies (PAS), Toronto CA. Poster session. 
43. 5/2018 Brasher M, Raffay T, Patwardhan A, Bada H, 
Giannone P, Westgate P, Abu Jawdeh EG. Response to First 
Dose of Albuterol in Mechanically Ventilated Preterm Infants. 
Pediatric Academic Societies (PAS), Toronto CA. Poster 
session. 
44. 5/2018 Montgomery K, Goldstein R, Abu Jawdeh EG, 
Yozwiak J, Patra A, Westgate P,  Ragsdale L. Impact of 
Individual Communication Styles on NICU Safety Culture 
Perception.  Pediatric Academic Societies (PAS), Toronto CA. 
Poster session. 
45. 5/2018 RHO Study Group. Use of Home Recorded 
Oximetry to Safely Discontinue Oxygen in Premature Infants 
with Bronchopulmonary Dysplasia. Eastern Society for Pediatric 
Research Meeting. Platform presentation. 
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RESEARCH SUPPORT  
 
Ongoing support 
 
Title:  A Low-cost Compact Diffuse Speckle Contrast Flow-
oximeter for Neonatal Brain Monitoring 
Source:  NIH R21 HD091118-01A1, April 2018 - Mar 2020 (PI, Yu) 
Role:  Co-Investigator 
 
Title:  Comparison of Aerosol delivery of Infasurf to Usual Care 
in Spontaneously Breathing RDS 
Source: ONY, June 2017- June 2019 (PI, Cummings) 
Role:  Principal Investigator (Site) 
 
Title:  A Randomized Trial of Outpatient Oxygen Weaning 
Strategies in Premature Infants.  
Source:  Patient-Centered Outcomes Research Institute (PCORI), 
January 2016 – Dec 2017 (PI, Rhein) 
Role:   Principal Investigator (Site) 
 
Title:  Effect of Delayed Cord Clamping on Chronic Intermittent 
Hypoxia in Extremely Premature Infants.  
Source:  The Gerber Foundation, Oct 2014 – Oct 2018. In no cost 
extension  
Role:   Principal Investigator 
 
Completed support 
 
Title:   Predictors of Intermittent Hypoxia in Premature Infants 
Source:  Children’s Miracle Network, Jan 2014 – Jan 2018. 
Role:   Principal Investigator 
 
Title: Intermittent Hypoxemia and Acute Kidney Injury (IHAKI 
study). 
Source:  Children’s Miracle Network. April 2016 – April 2017. 
 Role:   Principal Investigator (Multiple PI, Hanna) 
 
Title:  Perfusion index predicts the effect of red blood cell 
transfusions on oxygenation in preterm infants. 
Source:  CTSA UL1RR033173 (NCRR). July 2015-July 2016.  
Role:   Research Mentor 
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Title: Perfusion Index for Management of Hemodynamically 
Significant Patent Ductus Arteriosus in Extremely Preterm 
Infants.  
Source:  CTSA UL1RR033173 (NCRR). July 2015-July 2016.  
Role:   Research Mentor 
 
Title:  Infant Control of Breathing and Apnea Monitoring Program 
– Neonatology  
Source:  WHAS Crusades, July 2014.  
Role:   Principal Investigator 
 
 
Submitted grants under-review 
 
Title: Intermittent Hypoxemia in Preterm Infants: Role of 
Inflammation and Novel Treatment Strategy through a 
Randomized Placebo Controlled Trial (HIT Study).  
Source: NIH R01 Re-submitted March 2018. 
Role:    Principal Investigator 
 
 
Pending resubmission 
 
Title: Noncontact High-Density Optical Imaging of Neonatal 
Brain Function (PI, Yu) 
Source NIH R01 (30 percentile, pending resubmission July 2018) 
Role:  Co-Investigator 
 
 
COLLABORATIONS AND ACKNOWLEDGMENTS 
 
- Kaplan HC, Lannon C, Walsh MC, Donovan EF; Ohio Perinatal 
Quality Collaborative: Ohio statewide quality-improvement 
collaborative to reduce late-onset sepsis in preterm infants. 
Pediatrics 2011 Mar;127(3):427-35  
 
- Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey 
AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM: 
Immunogenicity of a single dose of tetravalent meningococcal 
serogroups A, C, W-135, and Y conjugate vaccine administered to 
2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide 
vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011 
Apr;30(4):e56-62. 
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GLOBAL HEALTH 
 
09/2006-06/2007 Volunteer Outreach Clinic (Public Service), Non-
Governmental Organization associated with 
American University of Beirut and active in refugee 
camps in Lebanon. The NGO provides health care 
and awareness in an outpatient facility located in 
underserved areas. 
   Member/Physician volunteer.  
 
03/2010  Peace Initiative (Iniciativas de Paz) (Public 
Service) 
Non-Governmental Organization (NGO) active in 
Central/Latin America 
Medical mission for disaster relief following 
Earthquake in Haiti. 
   Physician Volunteer  
 
 
08/2015 Shoulder to Shoulder (Hombro A Hombro) 
(Public Service) 
Non-Governmental Organization affiliated with 
University of Kentucky active in Ecuador. Medical 
Mission with ambulatory and stationed clinics; we 
cared for pediatric and adult patients in rural areas. 
Physician Volunteer; Supervised UK residents and 
students. 
  
Other Global Health Related 
 
- Case Western Reserve University, School of Medicine14th 
Management of Humanitarian Emergencies, Focus on Children and 
Families, A Course in Disaster Preparedness – 2010 
 
- Secondary Prevention of Type II Diabetes Mellitus in Lebanon with a 
Focus on the Practice of Comprehensive Care. Social and 
Preventive Medicine Public Health Project: field study and report. 
Elie Abu Jawdeh, Ibhar Al-Mheid, Bilal Ataya, Aline Baghdassarian, 
Omar Batal, Mohamad Elfakhani, Mentor: Iman Nuwayhid MD, 
DrPH. March 2006 
 
- “Exploring Childhood on the Street; When Street Becomes More 
Homey than Home”; American University of Beirut, Faculty of 
Medicine, Social and Preventive Medicine, Public Health Project. 
Field research project and report about street children in Lebanon. 
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Elie Abu Jawdeh, Joelle Abi Rached, Tarek Abou Hamdan, Joelle 
Amm, Aline Baghdassarian, George Mollayess Mentor: Iman 
Nuwayhid MD, DrPH. July 2003 
 
 
SPECIAL CERTIFICATIONS 
 
- University Hospitals of Cleveland - Rainbow Babies and Children’s 
Hospital,  
ECMO Physician Specialist (2011 - 2015) 
 
- Case Western Reserve University, Collaborative Institutional 
Training Initiative (CITI), Continuing Research Education Credit 
Program (CREC) (2008 – 2014) 
 
- American Academy of Pediatrics, Neonatal Resuscitation Program, 
Provider (2007 - present), Pediatric Advanced Life Support (2007 - 
2011) 
 
- University of Kentucky Collaborative Institutional Training Initiative 
(CITI) Completion Certificate (11/2014-present) 
 
 
INVITED PRESENTATIONS  
 
08/2014  University of Kentucky 
Department of Pediatrics 
Lexington, KY 
Neonatology Grand Rounds: Neonatal Apnea, 
Overview 
 
05/2015  American University of Beirut 
Beirut, Lebanon 
 Rounded with the NICU team and presented to 
residents/fellows  
   “Apnea and Reflux in Preterm Infants” 
 
05/2015  Contemporary Pediatrics Conference 
Lexington, KY 
Invited Speaker: “Gastroesophageal Reflux in 
Infants” 
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06/2015  Case Western Reserve University 
18th Management of Humanitarian 
Emergencies, Focus on Children, Women and 
Families. 
Cleveland, OH 
Invited Speaker: “Neonatal Resuscitation” 
   Moderator: “Case Discussion” 
 
09/2015 American Association of SIDS Prevention 
Physicians  
Pre-conference research session 
Naples, Florida 
   Invited Speaker: Intermittent Hypoxemia Research 
 
11/2015 UHC/AACN Nurse Residency Program Annual 
Conference, webinar 
   Lexington, KY 
Panelist; Life Adventure Center: A novel approach 
to improving team communication (Webinar) 
 
12/2015  University of Kentucky 
Department of Pediatrics 
Lexington, Kentucky 
Grand Rounds: Neonatal Apnea and Intermittent 
Hypoxemia 
 
02/2016  University of Kentucky 
Department of Pediatrics, Neonatology 
Lexington, KY 
  Neonatal Grand Rounds: Management of 
Gastroesophageal Reflux in the Preterm Infant 
 
05/2016   Case Western Reserve University 
19th Management of Humanitarian 
Emergencies, Focus on Children, Women and 
Families. 
Cleveland, OH 
Invited Speaker: “Neonatal Resuscitation” 
   Moderator: “Case Discussion” 
 
09/2016  American University of Beirut 
Department of Pediatrics  
Beirut, Lebanon 
Grand Rounds: Neonatal Apnea and Intermittent 
Hypoxemia 
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09/2016 American Association of SIDS Prevention 
Physicians Conference 
Naples, Florida 
Invited Speaker: Predictors Intermittent Hypoxemia 
Research 
    
01/2017   University of Kentucky 
Department of Pediatrics, Neonatology 
Lexington, KY 
 Grand Rounds: GERD? Probably Not! 
 
02/2017 National Collaborative for Perinatal Neonatal 
Network (NCPNN) Conference 
   Beirut, Lebanon 
Invited Speaker: Gastroesophageal Reflux in 
Preterm Infants 
Invited Speaker: Intermittent Hypoxemia in Preterm 
Infant 
 
05/2017  Case Western Reserve University 
Cleveland, OH 
Resident Workshop/Invited Speaker: Helping 
Babies Breathe; Neonatal 
   resuscitation in undeserved setting 
     
09/2017 American Association of SIDS Prevention 
Physicians Conference 
Naples, Florida 
Invited Speaker:  Intermittent Hypoxemia in 
Preterm Infants: Consequences 
 
